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Background 
Philosophers defined the eye as a window to the soul long before scientists 
addressed this cliché to determine its scientific basis and clinical relevance. 
Anatomically and developmentally, the eye is an extension of the central 
nervous system (brain). It consists of retinal ganglion cells, the axons of which 
form the optic nerve, whose fibres are, in effect, CNS axons. The eye has 
unique physical structures and a local array of surface molecules and cytokines, 
and is host to specialized immune responses similar to those in the brain and 
spinal cord. Several well-defined neurodegenerative conditions that affect the 
brain and spinal cord have manifestations in the eye.  
Multiple Sclerosis is a multi-factorial autoimmune disease leading to variable 
disability in early life. This disabling condition has impact on social and 
occupational life and eventually affects quality of life and vision. MRI is the 
main stay for early diagnosis and to determine response to treatment. Early 
diagnosis and subsequent treatment with disease modifying therapy has shown 
to have better outcomes on a long-term basis.  
The Retinal nerve fiber in the optic nerve and retina is devoid of myelin that 
makes it an ideal site for study of axonal damage. The loss of axons can be 
detected by a simple scan called, Optical coherence tomography that uses the 
principle of interferometry. This makes imaging free of radiation, less time 
consuming, cost effective and above all, OCT has a high inter-test and intra-test 
reliability ma 
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king it both specific and sensitive. OCT with different protocol can assess optic 
nerve, macula and choroid structurally which can then be correlated with 
sensitive functional measures of vision. 
This project aims to determine the role of structure and assessment of function 
of the visual pathway in Multiple sclerosis. It explores the role of vision studies 
in diagnosis of MS and to determine progression of disease. 
Further, we explore the correlation between visual outcomes with that of 
neurological outcome in multiple sclerosis. Sensitive visual testing for 
functional assessment along with precise technology of optical coherence 
tomography (scan of retina) for structural assessment has been used. Sub group 
analysis for the optic neuritis group and disease modifying treatment group has 
been studied. Intra and inter eye correlation have been derived to make a final 
conclusion for the role of vision study in Multiple Sclerosis. 
Does assessment of structure and function of visual pathway in MS have a 
future? Does it help in diagnosis, determining prognosis and response to 
treatment in  relapsing remitting Multiple sclerosis?? Does structure meet 
function!! 
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Abstract: 
  
Introduction: 
Multiple sclerosis is a disabling disease with impact on the social, financial and 
occupational life of an individual. Diagnosis of Multiple sclerosis even with the 
McDonald criteria, sometimes can take many years, by which time the patient 
has already accumulated significant disability. Hence the need for early 
diagnosis and prompt treatment for a better prognosis highlighted in different 
MS studies. 
Visual dysfunction in patients with Multiple sclerosis is a common finding. 
Asymptomatic visual loss has been highlighted in various studies.  In the United 
Kingdom, studies have focused on genetics, environmental factors, assessment 
of neurological state (EDSS, MSFC) along with MRI of the brain and spinal 
cord. There is no single study in the UK that has looked at the visual pathway in 
Multiple sclerosis and correlated with the neurological outcomes. 
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Aim: 
Correlation of structure and function of visual pathway in Multiple Sclerosis  
  
Methodology 
We recruited 55 (110 eyes) patients with relapsing remitting MS and 25 controls 
(50 eyes) into this project with specific inclusion and exclusion criteria. Power 
calculations were done based on the parameters used for the study. Coefficient 
of reliability and variability was tested prior to the study in a subset of control 
patients. Logistic regression model with odds ratio was used to assess the ability 
of each test to differentiate disease from control. Subgroup analysis was done 
for the optic neuritis group and the group receiving disease-modifying therapy. 
 
Function of the visual pathway was assessed using Sloan contrast charts along 
with HRR colour chart and HVF indices. Structure of the visual pathway was 
mainly assessed using different protocols from Optical Coherence Tomography. 
Ethical approval was obtained through the North Midlands IRAS and Keele 
University. 
 Results 
The structure of the visual pathway correlates significantly with function of 
vision. This in turn correlates with neurological function.  
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Visual tests are more sensitive than neurological testing by EDSS and hence can 
be used in diagnosis and to determine prognosis in RRMS. 
GCIP index, EDI OCT and posterior pole protocols on OCT have revealed 
useful and valuable information that can be translated into clinical use to 
manage patients with MS.  
Conclusion 
Sloan contrast charts and HRR colour testing are sensitive measures of disease 
progression. Visual field test indices on the Humphrey’s field test closely relate 
to RNFL thickness on posterior pole OCT.  
GCIP and EDI-OCT show different clinico-pathological staging in MS. 
Visual parameters have synergistic power in evaluating the disease process in 
MS. Visual testing for structure and function is a valuable addition to the 
routine assessment of MS patients. Visual assessment helps in detection of the 
spectrum of disease in MS with specifics to the range of manifestations and 
severities of illness .Multiple sclerosis like many other diseases exhibit the 
iceberg phenomenon. The iceberg phenomenon describes a situation in which a 
large percentage of a problem is subclinical or otherwise hidden from view. 
Thus, only the "tip of the iceberg" is apparent to the clinician. Visual 
assessments help in uncovering disease below the sea level by early detection 
and subsequent better disease control. Visual studies in MS using the 
parameters in this study must be considered for routine use in our day to day 
practice in diagnosis and managing patients more effectively. 
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1.1. Abbreviations  
 
AON  Acute optic neuritis 
AQ-4       Aquaporin-4 
ACTH Adrenocorticotrophic hormone 
ARR Annualised relapse rate 
AVP Anterior visual pathway 
BV Binocular vision  
BY Blue yellow 
BO Binocular optic neuritis 
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BSCB                         Blood spinal cord barrier  
BCNSB Blood central nervous system barrier 
BB-EC                        Blood brain endothelial cell 
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CCSVI     Central cerebrospinal venous insufficiency 
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CIS     Clinically isolate syndrome 
CRION     Chronic relapsing inflammatory optic neuritis 
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ELM External limiting membrane 
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HLADR2                          Human Leucocytic Antigen DR2 
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HVF Humphrey’s visual field 
HRR Hardy Rand Rittler chart 
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ITCB                                  Ishihara test for colour blindness 
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ILM Internal limiting membrane 
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INL Inner nuclear layer 
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ICD International classification of disease 
IV Intravenous 
LGN                                    Lateral geniculate nucleus 
LCVA   Low contrast visual acuity 
LogMAR  Logarithmic Minimal angle of resolution 
LC  Lamina cribrosa 
MRI  Magnetic resonance imaging 
MS  Multiple sclerosis 
MMP  Metalloproteinase 
MRV Magnetic resonance venography 
MHC Major histocompatibility complex 
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MSON Multiple sclerosis optic neuritis 
MSFC Multiple sclerosis functional composite 
MD Mean deviation 
mm millimeter 
MSQOL Multiple sclerosis quality of life 
MD Mean deviation 
MSFC Multiple sclerosis functional composite 
NON MS No optic neuritis Multiple sclerosis 
NMO Neuromyelitis optica 
IgG Immunoglobulin G 
NICE National institute of clinical excellence 
NFL Nerve fibre layer 
NHS National Health Service 
n/ N Number  
NEI National eye institute  
OD Right eye 
OS Left eye  
ONMS Optic neuritis Multiple sclerosis 
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OCT Optical coherence Tomography 
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ONL Outer nuclear layer 
OS Outer segment 
OT                                      Optic tract 
OCH                                   Optic Chiasm 
ON                                     Optic nerve 
OSMS                                Optico spinal Multiple sclerosis 
PPMS                                 Primary progressive Multiple sclerosis 
PMBC Papillomacular bundle complex 
PML                                   Progressive multifocal leucoencephalopathy 
PE                                       Pigment epithelium 
PSD                                    Pattern standard deviation 
P value                                Probability value 
PPRNFL                             Peripapillary retinal nerve fiber layer 
QOL                                   Quality of life 
QOV                                   Quality of vision 
RON                                    Relapsing optic neuritis 
RRMS                              Relapsing remitting multiple sclerosis 
ROS                                    Reactive oxygen  
RIS                                      Rod inner segment 
RGC Retinal ganglion cells 
RNFL Retinal nerve fibre layer 
RG Red green 
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SWAP Short wavelength automated perimetry 
SD Standard deviation 
SLCVA Sloan Low contrast visual acuity 
SF Short term fluctuation 
SITA  Swedish interactive threshold algorithm 
SD OCT                               Spectral domain Ocular coherence tomogram 
SLP Scanning laser polarimetry 
SION                                     Single isolated optic neuritis 
SPMS Secondary progressive Multiple sclerosis 
T-MRI Tesla Magnetic resonance imaging 
TV Total volume 
UHNM University Hospital of North midlands 
UK United Kingdom 
VA Visual acuity 
VEP                                       Visual Electro Physiology 
VF                                          Visual field 
VCC                                       Variable corneal compensation 
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2.1 Historical: The story of Multiple sclerosis and Vision 
The earliest of description of multiple sclerosis (MS), possibly, dates back to the 
14th century. A number of documents written before or shortly after the death 
of a young Dutch woman, Lidwina of Schiedam (1380-1433) 
1
surprise today’s 
clinicians by their very accurate description of symptoms which for the most 
part correspond to the clinical criteria prevailing nowadays for the diagnosis of 
multiple sclerosis. These could be the oldest known document, describing a case 
of multiple sclerosis (Medaer, 1979) 
2
.  
The virgin Lidwina of Schiedam (1380–1433)
 1
 fell while skating at age 16. She 
had an illness over the next 37 years that had many of the features we would 
now identify as multiple sclerosis, but the diagnosis must remain as “possible 
MS.” (Medaer)
 2
 
Pope Leo XIII canonized Saint Lidwina in 1890. She is listed in lives of the 
Saints, with “saint day,” April 14. Online Saints lists her as the patron saint of 
sickness, and because of her fall while skating, she is also the patron saint of 
figure skating. The United States Figure Skating Association has a medal 
featuring a picture of Lidwina. 
It was the French neurologist, Jean-Martin Charcot (1825–1893) 
3
, who made 
the first definite links between the symptoms of MS and the pathological 
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changes seen in post-mortem samples. He described the condition as “sclerose 
en plaques” and recognised MS as a distinct disease entity. Charcot’s 
contribution extended to the development of diagnostic criteria, which included 
the now-famous triad of “nystagmus, tremor and scanning speech”. He also 
identified many important histological features, including loss of myelin (Lublin 
2005)
 4
. 
Following Charcot’s landmark description, knowledge of MS became 
widespread and an entire chapter was dedicated to the condition in Gower’s 
“Manual of diseases of the Nervous system” (Gower 1893)
 5
. 
In 1845, before the invention of the Ophthalmoscope to visualise the back of the 
eye (fundus), diseases of the fundus, were impossible to recognise. Ancient 
physicians divided all eye diseases into “ophthalmia” or “blindness”.  
“Ophthalmia” included all varieties of conjunctival and corneal diseases 
recognised through inspection of the globe. “Blindness” referred to vision loss 
not based on an obvious change in the visible surface or media of the eye. 
Blindness was often considered a divine punishment for sin. Within that group, 
optic neuritis may have accounted for some of the “miraculous” spontaneous 
cures. 
The earliest references to optic nerve dysfunction as a mechanism for vision 
loss are found in Arabic texts of ophthalmology written in the ninth century. In 
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what is believed by some to be the first major textbook of ophthalmology, 
HunainIbn Is-Haq
6
 described three different forms of paralysis of the eye: those 
involving perception alone, those involving eye motion alone, and those 
involving both 
6
. In these early descriptions, he does not distinguish optic 
neuritis from other diseases of the posterior segment. However, there are 
specific references in this volume to pain and heaviness, “swelling” of the optic 
nerve, and the afferent pupillary defect 
6
 
Another Arabic writer, Ali Ibn Isa, referred to inflammation of the optic nerve, 
although he may have been describing papilledema, as he related “the cause of 
the blindness to the ventricles of the brain.” 
7
 In his textbook of ophthalmology, 
Isa describes various affections of the optic nerve, including those resulting 
from “warmth, cold, humidity etc”. 
In one of the earliest English language textbooks of ophthalmology, published 
in 1823, George Frick 
8
 wrote that optic neuritis, without the advantage of the 
ophthalmoscope, it was impossible to distinguish uveitis, migraine, retinal 
detachment, optic nerve and orbital apex disorders.  
Frick makes reference to severe pain in the orbit preceding vision loss, 
abnormal responses of the pupil to light, and the visual behaviour of patients 
with central scotoma. 
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Manuals written by Saunders 
9
 in 1821 and Littell
10
 in 1846 present a similarly 
confused impression of optic nerve and retinal diseases. 
Optic neuritis in post-ophthalmolscopic era 
With the widespread use of the ophthalmoscope in the second half of the 
nineteenth century, the various diseases affecting the optic nerve and retina 
became distinguishable. Von Graefe first described optic neuritis with some 
uniformity in 1860 
11
 and so did Nettleship in 1884 
12
. Nettleship acknowledged 
that Leber, Hutchinson, and Hock had previously described cases of optic 
neuritis. Nettleship points out confusion with tobacco amblyopia in Leber's 
writing and describes Hutchinson's series as having a variable group of patients 
and Hock as describing the characteristic pain of optic neuritis 
In 1930,Brain (journal)
 13
 wrote an in-depth review of the subject. Brain's 
review shows a shift in the emphasis of symptomatology with Charcot's triad of 
nystagmus, intentional tremor and dysarthria only being in minority of cases. 
The great variety of clinical features was now the important issue with common 
earliest symptom being parasthesia, motor and visual symptoms. Onset was 
recognised as usually sudden with relapses and remissions although cases of 
more insidious onset were becoming increasing recognised. 
Brain records a similar description of visual signs and symptoms. Amblyopia 
was still a common presenting symptom and pallor of the optic disc recorded in 
38 
 
33% to 58% of cases. Direct ophthalmoloscopy, visual acuity and visual field 
testing were still the main stay of examination of the visual system. The visual 
field in MS had received much attention and the detection of central scotoma 
and peripheral constriction has been explored. 
Klingman (1910)
 14
 had described paracentralscotoma, especially in the 
temporal field and Traquair (1925)
 15
 described retrobulbar neuritis affecting the 
optic chiasm and tract.  Cerebro-spinal fluid examination has been used since 
1920.A section on the investigation of MS in a chapter in Wilson’s book 
“Neurology”(1940)
 16
 was essentially unchanged from twenty years before. 
In the process of finding the cause and renaming the disease, Multiple sclerosis 
society was formed on the 30th July 1945
17
. The formation of these societies 
were consolidated in 1955  with publication of the monograph Multiple 
Sclerosis written by Douglas McAlpine (1890–1981), Nigel Compston (1918–
1986) and Charles Lumsden (1913–1974) since when the condition has 
universally been known as multiple sclerosis. 
John Kurtzke (1988) 
19
 has reviewed the history of the naming of multiple 
sclerosis and the classifications that were introduced for epidemiological 
purposes in order to weight the diagnosis in the absence of pathological proof. 
Allison and Millar (1954) 
20
 classified cases as early (few physical signs but a 
recent history of remitting symptoms), probable (soon changed to early 
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probable or latent: no reasonable doubt about the diagnosis), possible (findings 
suggesting the diagnosis and no other cause found but the history static or 
progressive and with insufficient evidence for scattered lesions) and discarded 
disseminated sclerosis. 
Until the mid-1980s, all surveys of multiple sclerosis used the Allison and 
Millar criteria with some modifications within categories, including 
introduction of the term (clinically) definite (Bauer et al 1965 
21
; Broman et al 
1965 
22
). The principles developed by John Kurtzke in classifying United States 
army veterans, on which consensus was later reached by a panel of examining 
neurologists, was formalized by Schumacher et al 
23 
who categorized definite 
cases as those showing objective evidence for disease affecting two or more 
white matter parts of the central nervous system (CNS), occurring in episodes 
separated by >24 hours or with progression over 6 months, in a person aged 
between 10 and 50 years at onset and in whom a competent observer can find 
no better explanation. (Compston  et al, McAlpine's Multiple Sclerosis 2006) 
24.
 
Visual evoked response (VER) have been recognised since the origin of 
electroencephalography (EEG). Adrian et al 
25
 demonstrated that regularly 
repeated flashes of light elicited electrical responses from the surface electrodes 
over the occipital cortex. Lord Adrian shared a noble prize with Sir Charles 
Sherrington shared a noble prize in 1932 for their work in Neurophysiology. 
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The type of reversing chequerboard pattern now commonly used owes it origin 
to the work of Spekreijse
26
and Cobb et al 
27
. These techniques made it possible 
to identify both the average response to a reversing chequerboard patterns well 
as the response to the onset and offset patterns. A paper by Halliday et al 
28
, on 
delayed evoked potential in optic neuritis was a driving force for laboratories to 
be set up with evoked potential tests. 
Imaging techniques such as Air encephalography, Boudin et al 
29
; myelography, 
Haughton et al
30
, were all studied as diagnostic aids but results were poor until 
the advent of Computed tomography (CT). However, CT was superseded within 
a few years by Magnetic resonance imaging (MRI) as first reported by Young et 
al.,
 31
. Imaging techniques have rapidly developed in the last thirty-five years 
and is one of the main stay in the diagnosis of MS. 
While the investigations to investigate brain and the spinal cord were gaining 
importance, there was a missing piece of information in this multi-modal, 
inflammatory, autoimmune condition that affected the central nervous system. 
The visual pathway, an embryological part of the forebrain was not looked into 
until recently in the 20th century gaining speed and refinement in the recent 
times. This opens a whole new concept of approaching the disease through the 
EYE, is the “window to the brain”. 
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2.2. Multiple Sclerosis, the disease 
Multiple sclerosis (MS) involves an immune mediated process in which an 
abnormal response of the body’s immune system is directed against the central 
nervous system (CNS), which is made up of the brain, spinal cord and optic 
nerves/pathway. The exact antigen or target that the immune cells are sensitised 
to remains unknown, which is why MS is considered by many experts to be 
"immune-mediated" rather than "autoimmune condition. 
Within the CNS, the immune system attacks myelin, the fatty substance that 
surrounds and insulates the nerve fibers as well as the nerve fibers themselves. 
The damaged myelin forms scar tissue (sclerosis), which gives the disease its 
name. When any part of the myelin sheath or nerve fiber is damaged or 
destroyed, nerve impulses travelling to and from the brain and spinal cord are 
distorted or interrupted, producing a wide variety of symptoms.
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2.3 Epidemiology 
An estimated 1.1 to 2.5 million people worldwide suffers from multiple 
sclerosis 
33
. Although the reason is unclear, this condition is more common in 
regions that are farther away from the equator. In Canada, parts of the northern 
United States, western and northern Europe, Russia, and south eastern Australia, 
the condition affects approximately 1 in 2,000 to 2,400 people. It is less 
common closer to the equator, such as in Asia, sub-Saharan Africa, and parts of 
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South America, where about 1 in 20,000 people are affected. For unknown 
reasons, most forms of multiple sclerosis affect women twice as often as men 
34
; however, women and men are equally affected by primary progressive MS. 
The prevalence of MS recorded in GPRD (general practice research 
database)has  increased by about 2.4% per year, reaching 285.8 in women and 
113.1 in men per 100 000 by 2010. There was a consistent upward trend in 
incidence of MS reaching 11.52 in women and 4.84 in men per 100, 000/year 
by 2010. Peak incidence occurred between ages 40 and 50 years and maximum 
prevalence between ages 55 and 60 years. Women accounted for 72% of 
prevalent and 71% of incident cases. Scotland had the highest incidence and 
prevalence rates in the UK. An estimate that  
126,669 people were living with MS in the UK in 2010 (203.4 per 100 000 
population) and that 6003 new cases were diagnosed that year (9.64 per 100 
000/year). There is an increasing population living longer with MS, which has 
important implications for resource allocation for MS in the UK
35
 
 
2.4 Etiology 
Etiology of multiple sclerosis (MS) is still unknown, but both the genetic and 
environmental fields contribute to the emergence of the disease. Of the 
environment, in particular, prospective cohort studies revealed in recent years 
that prior infection with Epstein-Barr virus (EBV) 
35
, deficiency of vitamin D 
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36
, and tobacco smoking 
are
 important for the generation of MS in a 
multifactorial way. With diet, as one of the possible causes of MS, the situation 
is at present inconsistent. In many reviewing articles of its epidemiology, diet is 
also mentioned as a factor of importance. Other risk factors relate to age, gender 
and ethnicity. Women are 2 to 3 times more likely to develop MS than men. MS 
usually strikes between the ages of 20 and 40 with higher risk in patients of 
northern Europe descent. 
 
2.5 Genetic etiology 
Genetic of MS: 
The MS genetic consortium and our research group have thrown light into the 
role of genetics in MS
37, 38.
 
 
Genetics of Optico spinal MS (OSMS) 
Multiple Sclerosis (MS) is a demyelinating disease of the central nervous 
system (CNS) while Neuromyelitisoptica (NMO) selectively affects the optic 
nerves and spinal cord. In Asians, MS is rare; however, when it appears, the 
selective and severe involvement of the optic nerves and spinal cord is 
characteristic. This form, termed optico-spinal MS 
(OSMS) has similar features to the relapsing form of NMO in Western 
populations. 
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Because NMO-IgG have been reported to be present in 30-60% of OSMS 
patients, OSMS in Asians has been suggested to be the same entity as NMO 
39
. 
The Opticospinal multiple sclerosis showed a significantly higher age of onset, 
higher expanded disability status scale scores and higher CSF cell counts and 
protein content than the Western type multiple sclerosis. On brain and spinal 
cord MRI, the opticospinal multiple sclerosis showed a significantly lower 
number of brain lesions, but a higher frequency of gadolinium-enhancement of 
the optic nerve and a higher frequency of spinal cord atrophy than in Western 
type multiple sclerosis. The frequency of the HLADPB1*0501 allele was found 
to be significantly greater in opticospinal multiple sclerosis 
(93%) than in healthy controls (63%, corrected P value = 0.0091 and relative 
risk = 7.9), but not in Western type multiple sclerosis (66%) or spinal multiple 
sclerosis (82%) 
 
 2.6 Patho-physiology of MS 
The primary cause of MS is currently unknown. Current models can be divided 
in two groups, Inside out and Outside-in. 
 In the inside-out model, it is hypothesised that a problem in the CNS cells 
produces an immune response that destroys myelin and finally breaks the blood-
brain barrier (BBB). In the outside-in models, an external factor produce BBB 
leaks, enters the CNS, and destroys myelin and axons. 
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Direct influence of immune cells on the BBB 
The BBB has direct influence from the effect of cytokines, ROS and matrix 
metallo-proteinases (MMPs) produced by peripheral blood mononuclear cells 
(PBMCs) that can directly disrupt components of the BBB or act on receptors 
expressed by BBBECs (Fig. 2.1) 
 
Figure 2.1: Blood brain barrier (Textbook of Neurology (1997). "The Blood-Brain 
Barrier in Neuroinflammatory Diseases") 
 
2.7 The blood -brain barrier 
The central nervous system (CNS), along with testis and eye, is considered an 
immune privileged site. The presence of a blood–brain barrier (BBB) restricts 
the movement of soluble mediators and leukocytes from the periphery to the 
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CNS. Despite the presence of this tightly regulated BBB, leukocyte entry into 
the CNS is an early event in multiple sclerosis (MS). Acute MS lesions, 
featuring areas of demyelination, axonal loss and immune cell infiltrates, 
display BBB disruption as evidenced by in vivo gadolinium uptake on magnetic 
resonance imaging (MRI) and post-mortem evidence of focal micro-vascular 
leakage. Whether BBB dysfunction precedes immune cell infiltration or is the 
consequence of perivascular leukocyte accumulation remains to be established. 
The BCNSB has two further barrier elements: (i) a metabolic barrier that 
contains a complex array of enzymes (including acetylcholinesterase, alkaline 
phosphatase, γ-glutamyltranspeptidase, and 
Monoamine oxidases) that degrade different chemical compounds thus altering 
their pharmacological activity and (ii) a transport barrier that contains a variety 
of efflux transporters, including P-glycoprotein and breast cancer resistance 
protein 
40
. 
Tight junctions are the critical component of the BCNSB as they control 
paracellular diffusion and maintain the structural and functional polarity of the 
specialized endothelial cells of the BBB and BSCB. Thus, the BCNSB 
contributes to the homeostasis of the parenchyma of the brain and spinal cord 
and provides protection against many toxic compounds and pathogens
41, 42. 
Indeed, the BCNSB is largely impermeable to compounds that are not lipophilic 
and have a molecular weight greater than 450 Da. This presents a major 
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challenge for CNS drug discovery
43, 44
. Early pathologists championed the 
concept of vascular lesions being an important component of the MS attack. 
Dawson 
45 
showed that inflammatory cells clustered around veins in the center 
of the demyelinated plaque. Putnam and Adler 
46
 carefully reconstructed serial 
brain sections from MS patients, and showed that fibrin deposits surrounded the 
inflamed vessels. Magnetic resonance imaging has confirmed these early 
pathological studies. Correlation of venous pathology with MS lesions is 
possible with MR venography, which takes advantage of the difference between 
oxygenated and deoxygenated blood to visualize venous blood. In most MS 
lesions, venogram shows a vein in the center of the lesions. This pattern is not 
specific for MS since a similar pattern with venule involvement occurs with 
hypoxic ischemic white matter lesions. However, in contrast to MS lesions, 
ischemic white matter lesions showed no consistent relationship to the shape 
and location of the veins 
46
. A recent study using a 7-T MRI showed that T2*-
weighted images can reliably distinguish all patients with clinically definite MS. 
Small venules in the center of lesions are visualized using T2*-weighted MRI 
because of the paramagnetic effect of deoxy-hemoglobin. Those patients have 
>40% of the MS lesions in a perivenous location, while in those without clinical 
MS, <40% of the lesions appeared perivenous
47.
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2.8 The blood ocular barrier  
The blood ocular barrier is composed of the blood-aqueous barrier and the 
blood-retinal barrier, protecting the eye from entry of toxic substances and 
maintaining the homeostatic control that underpins the ocular physiology
48, 49
. 
The blood-aqueous barrier is formed by the non-pigmented epithelium of the 
ciliary body, the posterior iris epithelium, the endothelium of the iris vessels 
with tight junctions of the leaky type, and the endothelium of Schlemm’s canal. 
The blood-retinal barrier consists of the retinal pigment epithelium (outer 
barrier) and the endothelial membrane of the retinal vessels (inner barrier), both 
with tight junctions of the non leaky type. The two functional barriers restrict 
the movement of blood elements to the intraocular chambers 
50
 and explain why 
drugs administered orally or intravenously can hardly reach therapeutic levels in 
intraocular tissues 
Endothelial barriers, including the blood-brain barrier (BBB), the blood-retinal 
barrier (BRB), and the blood-nerve barrier (BNB), shield the nervous system 
from circulating agents, such as immunoglobulins, that might prove toxic. 
These barriers also prevent the entry of resting leukocytes from the circulation. 
Activated T lymphocytes, however, are able to penetrate the barriers through 
the action of their surface enzymes and adhesion molecules; it is generally 
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assumed that there are no implications for vascular integrity if there is no 
antigen recognition in the tissue. 
Magnetic resonance imaging of individuals with multiple sclerosis (MS), a 
relatively common inflammatory demyelinating disease of the CNS, has 
revealed that breakdown of the BBB is the earliest demonstrable abnormality in 
the formation of new lesions and in the extension of old lesions. Given that this 
breakdown of the BBB is thought to play a fundamental role in the pathogenesis 
of MS, it is important to understand the mechanism by which it occurs. 
Breakdown of the BBB is always associated with cellular infiltration in 
individuals with MS. 
 
The retina is an ideal tissue in which to characterize the microvascular and 
cellular responses of the CNS to an intravascular injection of activated T cells 
of non-neural specificity, because it is possible to visualize the entire retinal 
vascular plexus with the normal relations among the glial, vascular, and 
neuronal elements intact. In particular, with the use of intravascular barrier 
tracers and cell-specific reagents 
51
, it is possible to co-localize sites of cellular 
accumulation with sites of breakdown of the BRB. The retinal whole mount 
technique has the additional advantage that arteries, capillaries, and venules are 
readily identified, thereby allowing accurate localization of specific cellular and 
vascular changes to specific regions of the CNS microvasculature. Taken 
together, these observations lead us to suggest that microglia are not the cells 
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that induce the immune response even when the target antigen is encountered; 
rather, other cells, such as the peri-vascular cells that constitutively express 
MHC II or circulating monocytes, are responsible for initiation of the immune 
response. 
 
 
 
Figure 2.2: Blood ocular barrier (Textbook of Neurology (1997). "The Blood-Brain Barrier 
in Neuroinflammatory Diseases") 
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2.9 Recent theory of MS 
CCSVI (central venous insufficiency)  
In 2009, Italian researcher Paolo Zamboni, first introduced the idea that CCSVI 
might cause MS 
52
, or make its symptoms worse. When he used ultrasound to 
compare the blood vessels of people with and without MS, he found abnormal 
blood flow in 100% of the people with MS, but in 0% of people without MS. 
CCSVI stands for chronic cerebrospinal venous insufficiency. It's a narrowing 
of veins in the neck and chest that carry blood away from the brain and spinal 
cord. The theory is that when blood flow is slowed, it backs up into the brain 
and spinal cord and leads to oxygen loss and iron deposits in the brain. 
In 2008, two open-minded and forward-thinking MS researchers at the 
University of  Buffalo, Dr Robert Zivadinov and Dr Bianca Weinstock-
Guttman, recognized the great potential importance of Dr Zamboni’s research 
and decided to undertake a major study to see if Dr Zamboni’s impressive 
results could be replicated. In 2010 some of the main results of Phase 1 of the 
Buffalo Study were made public in a press release. These results consist of: 
1) 55% of persons with MS in the study had CCSVI 
2) 22% of healthy controls had CCSVI 
3) 10% of subjects tested (50) were classified as borderline and were included 
in the non-CCSVI category for the above statistics. When these individuals 
were excluded from the statistical analysis, 
62% of persons with MS had CCSVI and 26% of healthy controls had CCSVI. 
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4) 38% of those with Clinically Isolated Syndrome (CIS) (start MS in most 
cases) had CCSVI 
5) 80% of those with more advanced MS (EDDS levels not specified) had 
CCSVI 
The new Lancet study 
53
, including 177 subjects, 79 with multiple sclerosis, 55 
siblings, and 43 unrelated controls from three centers in Canada is one of the 
largest studies of CCSVI and MS. The results of this study are also completely 
negative – no correlation between CCSVI and MS. They found that catheter 
venography criteria for chronic cerebrospinal venous insufficiency were 
positive for one of 65 (2%) people with multiple sclerosis, one of 46 (2%) 
siblings, and one of 32 (3%) unrelated controls (p=1•0 for all comparisons). 
Greater than 50% narrowing of any major vein was present in 48 of 65 (74%) 
people with multiple sclerosis, 31 of 47 (66%) siblings (p=0•41 for comparison 
with patients with multiple sclerosis), and 26 of 37 (70%) unrelated controls 
(p=0•82). 
It’s interesting that about 2/3 of people had greater than 50% narrowing, 
meaning that such narrowing is a common occurrence and it not necessarily 
correlated with any disease. This study suggests that Zamboni was simply 
making an incidental finding of a common benign anatomical variant that is 
neither pathological nor related to MS. 
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2.10   Old theories of MS 
The cause why the normal appearing areas appear in the brain is unknown. 
Historically, several theories about how this happens have been presented. 
Old blood flow theories 
Venous pathology has been associated with MS for more than a century. 
Pathologist Georg Eduard Rindfleisch noted in 1863 that the inflammation-
associated lesions were distributed around veins 
54 
.Some other authors like 
Tracy Putnam 
55
 pointed to venous obstructions. 
Some authors like Franz Schelling proposed a mechanical damage procedure 
based on violent blood reflux 
56. 
 Later the focus moved to softer hemodynamic 
abnormalities, which were showing precede changes in sub-cortical gray matter 
57
 and in substantia nigra 
58   
 
Endothelial theory 
The various theories such as CSF flow theory, CSF composition, Kir.4 theory 
and primary neuro-degeneration theories are worth a mention 
59 
Iron in MS 
MRI and histological studies have shown global alterations in iron levels in the 
brains of patients with multiple sclerosis (MS), including increases in the iron 
stored by macrophages and microglia. Excessive free iron can be toxic, and 
accumulation of iron in MS has generally been thought to be 
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detrimental. However, iron maintains the integrity of oligodendrocytes and 
myelin, and facilitates their regeneration following injury. The extracellular 
matrix, a key regulator of remyelination, might also modulate iron levels. 
In MS, it is still not clear whether iron deposition is an epiphenomenon or a 
mediator of disease processes 
60
. 
2.11 Pathology 
The pathological hallmark of demyelinating diseases of the central nervous 
system is characterized by loss of myelin with variable loss of axons 
61
. The 
main demyelinating disease of the CNS is multiple sclerosis (MS) and its 
variants. Its counterpart in the peripheral nervous system is inflammatory poly-
radiculo-neuropathy (Guillain-Barré syndrome-GBS) and its chronic variants. 
MS and GBS are autoimmune inflammatory diseases. There are also virus-
induced demyelinative diseases, such as progressive multifocal 
leukoencephalopathy (PML). Multifocal lesions, the MS plaques, characterize 
the pathology. The usual evolution of the MS plaque is as follows: in the acute 
phase, activated mononuclear cells, including lymphocytes, microglia, and 
macrophages destroy myelin and, to a variable degree, oligodendrocytes. 
Myelin debris are picked up by macrophages and degraded. At an early stage, 
macrophages contain myelin fragments; later, they contain proteins and lipids 
from chemical degradation of myelin. This evolution takes a few weeks. With 
time, gliosis develops, and plaques reach a burned-out stage consisting of 
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demyelinated axons traversing glial scar tissue. Remaining oligodendrocytes 
attempt to make new myelin. If the inflammatory process is arrested at an early 
phase, plaques are partially 
remyelinated. In more advanced lesions, remyelination is ineffective because 
gliosis creates a barrier between the myelin producing cells and their axonal 
targets. The pathological process may be arrested at any time, sometimes after 
partial demyelination. 
The pattern described above is variable. In most cases, the inflammatory 
reaction subsides only to appear at another location or at another time. Some 
lesions expand at their periphery while activity in their center dies down. In 
fulminant MS cases, large lesions with diffuse activity develop and expand 
inexorably. Although myelin is preferentially affected, axonal loss is significant, 
and necrosis and cavitation may develop, especially in severe, acute lesions. 
 
Diagnosis of acute MS, especially with stereotactic needle biopsies, may be 
tricky because cellularity and reactive astrocytes in the lesions may be 
misinterpreted as a neoplasm. Activity is often confined to the borders of 
plaques. 
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Figure 2.3: Perivascular lymphocytes in an active MS plaque. 
 
Figure 2.4: Histopathology of MS plaque. Normal myelin stains deep blue. 
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2.12 Histopathological classification of demyelination 
 
Demyelinating diseases relating to MS in the old system have been classified 
histologically by pathologist into various groups 
62
: 
 Acute fulminant type (Marburg Type): A very rare form of MS which may 
be less uncommon than previously thought, first described in 1906 by Otto 
Marburg. Symptoms may be preceded by fevers, and is typically monophasic. 
Pathologically shows areas of demyelination with marked macrophage 
infiltration and extensive axonal damage and necrosis. Extensive confluent 
areas tumefactive demyelination is seen with mass effect and defined rings and 
incomplete ring enhancement with rarity of small lesions on brain imaging 
(MRI). Death from involvement of the brain stem or due to marked mass effect 
and herniation is common. 
 
Acute disseminated encephalomyelitis (ADEM): An extremely rare 
progressive demyelinating process that begins in childhood. Symptoms include 
aphasia, balance instability, dementia, headache, incontinence, personality 
changes, seizures, tremors, visual disturbances and weakness.  
Posner proposed in 1985, all six criteria must be met for diagnosis; 
1. One to two large plaques: should be in each brain hemisphere predominantly 
in centrum semiovale. Lesions are greater than 2 cm in 2/3 dimensions 
2. No additional lesions identified 
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3. No peripheral nervous system abnormality 
4. Normal adrenal function 
5. Normal serum long chain fatty acids 
6. Histological changes consistent with sub-acute/chronic myelino-clastic 
diffuse sclerosis. 
Schilder’s type patients have poor prognosis and current recommendations are 
high dose corticosteroids and supportive care. 
 
 Balo concentric sclerosis (BCS) is a rare with presentation closely resembles 
acute Marburg MS, with rapid progression and sometimes fulminant course. 
Histopathology reveals concentric layers of alternating demyelination and 
preserved myelin. 
 
 Optico spinal multiple sclerosis (OSMS) is a spectrum of demyelinating 
disease with similar clinical and imaging features to Neuromyelitis optica 
(NMO). The identification of anti-aquaporin 4 IgG antibodies in NMO has 
naturally led to them being sought in patients with OSMS, with varying results, 
ranging form 35-90%. Whether or not NMO and OSMS are the same disease 
remains to be fully elucidated. 
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2.13 Clinical features and differential diagnosis 
 
MS can cause almost any neurological symptom since it can affect any area of 
the brain, optic nerve, and spinal cord. 
Broadly, the initial symptoms include, in decreasing order of frequency: 
• Weakness in one of more limbs 
• Blurred vision relating Optic/ retrobulbar neuritis 
• Tingling and numbness (paraesthesia) 
• Double vision (diplopia), nystagmus 
• Vertigo 
• Disturbance of micturition 
• Spasticity, 
• Fatigue 
• Pain 
• Uhthoff sign: transient impairment of any function due to increase body 
temperature due to exercise, hot bath, hot weather. 
• Lhermitte's sign 
• Mental changes including depression, dementia, and memory loss 
With the diversity in symptoms, signs and clinical course MS provides a source 
of misdiagnosis for even the experienced clinicians. 
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2.14 Clinical classification of MS 
They are important not only for prognosis but also for treatment decisions. In 
1996, the United States National Multiple Sclerosis Society described four 
clinical courses 
63. 
An international panel later reviewed this set in 2013, adding 
clinically isolate syndrome (CIS) and radiologically isolate syndrome (RIS) as 
phenotypes. Patients usually experience a first neurologic event suggestive of 
MS known as Clinically Isolated Syndrome (CIS). It lasts for at least 24 hours, 
with symptoms and signs indicating either a single lesion (monofocal) or more 
than one lesion (multifocal) within the central nervous system 
64
.  
 
The four clinical courses are 
• Relapsing-remitting (RRMS) 
• Secondary progressive (SPMS) 
• Primary progressive (PPMS) 
• Progressive relapsing. 
 
The relapsing-remitting course is the most common and carries the best 
prognosis. However, although symptoms remit, there is usually a mild residual 
deficit. Over time, these mild deficits produce disability. After about 6 to 10 
years, approximately 30% to 40%of cases of relapsing-remitting MS evolve into 
a progressive form (secondary progressive). 
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In the progressive form, symptoms worsen insidiously without a clear period of 
remission. Relapses may be superimposed on a background of functional 
decline. In the primary progressive form, there are no periods of remission. 
Instead, steady progression of symptoms leads to disability from the start. 
 
Table 2.6: Illustration of different clinical courses of multiple sclerosis. 
Adapted from Lublin FD, et al.  
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2.15 Diagnosis of MS 
There is no pathognomonic clinical, laboratory, or imaging finding in MS. The 
diagnosis ultimately is a clinical decision based upon weighing
65
 the factors that 
support the diagnosis against those that fail to support it or point to the 
possibility of an alternative diagnosis 
66
(NMO and OSMS). 
The Schumacher criteria/ Poser from 1965 capture the essence of the diagnosis 
of MS: CNS lesions disseminated in space and time, and the elimination of 
alternative diagnosis. The Schumacher criteria required an age range between 
10 and 50 years and objective abnormalities on examination, which are now 
outdated. However, the main concepts 
captured by these criteria remain relevant today. 
The criteria from the International Panel on MS Diagnosis, also called the 
McDonald Criteria, are a set of diagnostic criteria for MS that incorporate the 
clinical characteristics alone or in combination with MRI features. 
10 Revisions were made in 2005 and again in 2010 as a reflection of an 
increased understanding of the natural history of MS revealed by the MRI and 
clinical progression, and improved MRI techniques. The latest version of the 
McDonald Criteria (2010) has simplified the diagnostic process, allowing MS to 
be diagnosed earlier (Table 2.7) 
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Table 2.7: 2010 Revised McDonald Criteria for the Diagnosis of Multiple 
Sclerosis  
 
  
Clinical Presentation   Additional Data Needed for MS Diagnosis  
 Two or more 
attacks  
 
 Objective clinical 
evidence of 2 or 
more lesions with 
reasonable 
historical evidence 
of a prior attack  
 
 
 
 
 
None; clinical evidence will suffice. Additional 
evidence (e.g., brain MRI) desirable, 
but must be consistent with MS 
 
 
 Two or more 
attacks  
 
 Objective clinical 
evidence of 1 
lesion  
 
 
 
 
Dissemination in space demonstrated by MRI or 
Await further clinical attack implicating a different 
site 
 
 
 One attack  
 
 Objective clinical 
evidence of 2 or 
more lesions  
 
 
 
 
Dissemination in time demonstrated by 
MRI or second clinical attack 
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  
 One attack  
 Objective clinical 
evidence of 1 
lesion (clinically 
isolated 
syndrome)  
 
 
 
 
 
Dissemination in space demonstrated by 
 
 
 
MRI or await a second clinical attack 
implicating a different CNS site 
 
 
 
and 
 
 
 
Dissemination in time, demonstrated by 
MRI or second clinical attack 
 
 
 
 · Insidious neurologic 
progression suggestive 
of MS 
 
 
One year of disease progression and 
dissemination in space, demonstrated by 2 
of the following:  
 One or more T2 lesions in brain, in 
regions characteristic of MS  
 Two or more T2 focal lesions in 
spinal cord  
 Positive CSF  
 
  
Notes: An attack is defined as a neurological disturbance of the kind seen in MS. 
It can be documented by subjective report or by objective observation, but it 
must last for at least 24 hours. Pseudo attacks and single paroxysmal episodes 
must be excluded. To be considered separate attacks, at least 30 days must 
elapse between onset of one event and onset of another event. 
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After a single episode of demyelination, certain findings on one MRI can help 
fulfill the diagnostic criteria for MS, even before a second clinical episode or 
new MRI lesion. The revisions also preserve diagnostic sensitivity and 
specificity
67
 and address their applicability across different populations, 
allowing for more uniform and widespread use across groups. 
 
2.16 Conditions that mimic MS and may be considered in the differentials
68
 
 
  
Diseases capable of causing multiple lesions of CNS often causing relapsing 
and remitting course 
- Systemic Lupus erythematosus 
- Primary Sjogren’s Syndrome 
- Polyarteritisnodosa 
- Behcets disease 
- AIDS 
- Sarcoidosis 
- Devic's disease (NMO) 
- Lyme's disease 
- Sub-acute myeloencephalitis 
- Cerebrovascular disease 
- Meningovascular syphilis 
- Remote effects of carcinoma 
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2 Systematised diseases 
- Hereditary spino-cerebellar ataxia 
- Subacute combined degeneration of Spinal cord 
- Leukodystrophy 
 
3 Single lesion of central nervous system with a relapsing and remitting 
course 
- Tumours 
- Arterio-venous malformations 
4 Single lesion of central nervous system with a progressive course 
- Tumours 
- Cervical spondylotic myelopathy 
- Chiari Malformations 
5 Mono-symptomatic presentations 
- Visual failure 
- Diplopia 
- Sensory symptoms 
6 Non organic symptoms 
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2.17 Management of MS 
Multiple sclerosis is a complex disease and management is mainly led by a 
multidisciplinary team of consultant neurologists, MS nurses, physiotherapists 
and occupational therapists, speech and language therapists, psychologists, 
dietitians, social care and continence specialists and General practitioners. 
Management of MS requires a constant counselling and update to the affected 
and their family members in addition to the medical management of the 
condition.  
Medical management can be divided into 2 categories: 
a) Treat acute symptoms with steroids 
NICE recommends use of intravenous and oral steroids for acute relapses. 
1gram IV methyl prednisolone is given for 3 days for confirmed relapses. 
Use of steroids is controversial as recent research evidence suggests a delay in 
re-myelination process and a long term build-up of disability. On the contrary, it 
is not clear if untreated, the patients would still accumulate disability. Other 
treatment for acute relapses includes immunoglobulins, plasma exchange and 
ACTH (Adrenocortico trophic hormones). 
 
b)  Long term medical management using Disease modifying therapy 
(DMT) along with symptom management and rehabilitation. 
Long-term treatment with disease modifying agent is made after careful 
consideration of disease stage, tolerance, anticipated adverse effects and life 
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style. Disease-modifying agents aim to slow the progression of the disease, 
reduce accumulation of lesions in the brain and spinal cord as measured by MRI 
and also reduce acute attacks. 
The DMT's currently in use are: 
a) Interferons: Interferon beta-1b (beta interferon)
67
 and Interferon beta-
1a (Avonex, Rebif) 
Mechanism of action: The exact mechanism of action is unknown, but 
they inhibit the pro-inflammatory cascade including gamma interferon . 
Caution: Patients with uncontrolled depression. 
Adverse effect beta interferons: Include flu-like symptoms, elevated liver 
enzymes, and injection site reactions. 
Adverse effects Rebif: Fewer flu-like symptoms. Other adverse effects 
include hepatic and hematologic complications, which are usually 
asymptomatic. 
b) Fingolimod (Gilenya): 
Mechanism of action: First oral treatment which modulates a subset of G-
protein receptors leading to B lymphocyte sequestration in the lymph 
nodes and reduces their migration in the nervous system. 
Adverse reaction: Fingolimod is associated with bradycardia and 
prolonged QT syndrome. 
Caution: Absolute lymphocyte count needs to be monitored which can be 
a major drawback 
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c) Natalizumab (Tysabri)
 68
: 
This monoclonal antibody binds to α-4 integrin and inhibits binding to its 
receptors. This monotherapy delays physical disability and decreases 
frequency of acute attacks. Natalizumab is associated with progressive 
multifocal leukoencephalopathy and is only available via a restricted 
prescribing program called TOUCH. Standard dose for the IV infusion is 
300mg over one hour every four weeks. 
d) Glatiramer acetate (Copaxone)
 18
: 
This is a polypeptide involved in immune process modification in the 
pathogenesis of MS. It has been shown to decrease the acute exacerbation 
rate by 29% in patients with RRMS and is shown to reduce their 
frequency. However, it is used as an  FDA approved second line of 
treatment in RRMS in patients showing convincing changes on the MRI .  
 
e) Daclizumab and Ocrelizumab: These are monoclonal antibodies 
currently being studied that also have shown promise for patients with 
MS. 
 
f) Cladribine, Laquinimod 
69
: These are the few new agents under 
investigation. 
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      Chapter 3: The visual system in Multiple Sclerosis 
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3.1. Introduction 
The human visual system relies on a constant and rapid flow of information 
along the visual pathway. The complex visual system can be delineated into 2 
major pathways, based on the presence and absence of myelin sheath. 
a) The pre -lamina cribrosa pathway is composed of un-myelinated nerve fiber, 
extending from the retinal ganglion cells (RGC), both peripheral retina and 
central macular retina, to its entry into the optic nerve head (ONH) until it 
reaches the lamina cribrosa (LC). 
It is rich in neurons and axons of the ganglionic cells (90%) along with 
supporting Muller and glial cells. 
b) The post lamina cribrosa pathway is composed of myelinated nerve fiber, 
extending beyond the lamina cribrosa and includes the optic nerve (ON), optic 
chiasm (OCH), optic tract (OT) and visual cortex (VC). 
It is a mixture of myelin and axons as it is with the rest of the central nervous 
system 
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3.2. Eye “the window to the brain” : Philosophers defined the eye as a 
“window to the soul” long before scientists addressed this cliché to determine 
its scientific basis and clinical relevance. Anatomically and developmentally, 
the eye is an extension from the brain. The retina axons are in effect the CNS 
axons. The eye is the only part of the brain that can be seen directly via the optic 
nerve and the retina, which makes the eye unique 
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3.3. Eye “a model of neuro-degeneration in MS”: The anterior visual system 
is a frequent target of the MS disease process that almost all patients with MS
71
 
are found to have characteristic MS changes in the retina and optic nerve, 
regardless of whether they have previously experienced acute optic neuritis 
(AON) 
72, 73—although as many as 30–70% of patients with MS will, in fact, 
have inflammatory optic neuritis during the course of their disease 
74
. The 
pathophysiology of multiple sclerosis (MS) is characterized by demyelination, 
which culminates in a reduction in axonal transmission. Axonal and neuronal 
degeneration seem to be concomitant features of MS and are probably the 
pathological processes responsible for permanent disability in this disease. The 
retina is unique within the CNS in that it contains axons and glia but no myelin, 
and it is, therefore, an ideal structure to visualize the processes of 
neurodegeneration, neuroprotection, and potentially even neurorestoration.  
In particular, the retina enables us to investigate a specific compartment of the 
CNS that is targeted by the disease process
 72
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3.4. Visual Symptoms in MS 
MS affects the visual system in a large proportion of patients to an extent that 
visual symptom is the first presenting feature in 15-20% of the patient and 50% 
of the patients have visual problems during the course of the disease. With 
visual system gaining importance in diagnosis and management of MS, it has 
become evident that asymptomatic/ sub-clinical visual loss is a classical feature 
in MS. This in-turn affects quality of vision and life in MS. 
The Ophthalmic manifestations of multiple sclerosis can be divided into two 
main categories: those that affect the visual sensory system and those that affect 
the ocular motor system. 
Visual sensory system involvement in the order of occurrence: 
1) Optic neuritis 
Demyelinating optic neuritis can be considered in three categories: 
a) Acute 
b) Chronic 
c) Sub-clinical (asymptomatic) 
2) Choroidal and retinal lesions 
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3) Posterior uveitis that includes branch retinal occlusion, neovascularization, 
retinal venous sheathing 
4) Intermediate Uveitis (Pars Planitis) 
Pars planitis is a condition characterized by intraocular inflammation consisting 
of cells and debris in the vitreous, condensation of the vitreous along the pars 
plana, and varying degrees of periphlebitis. There is usually little or no 
inflammation in the anterior chamber. The condition can have numerous 
sequele that may threaten vision, including cataract formation, development of 
epiretinal membrane in the macula, and cystoid macular edema. Malinowski et 
al 
75
 found that 6.2% of patients with pars planitis were at risk of developing 
MS. Malinowski  also found a strong association of pars planitis with HLA--
DR2 and the temporal development of MS  . Genetic predisposition in MS has 
always been a critical concern in aetiology and progress of the disease. 
Kheradvar et al 
76
 presented relations between human leukocyte antigen (HLA), 
optic neuritis (ON) and MS in the Iranian population. These studies strongly 
suggests the association among DR2, A23 and B21 allele and the evolution of 
ON to MS. High prevalence of A23 and DR2 alleles in clinically definite MS 
patients compared with the normal population may suggest an important role for 
these alleles in the development of MS. The study suggests B51 as a protective 
factor against development of ON in the normal population 
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3.5 Oculomotor system involvement: 
Patients with multiple sclerosis may develop disorders of fixation, ocular 
motility and ocular alignment. Nystagmus is the most common disorder of 
fixation associated with MS, including upbeat nystagmus, downbeat nystagmus, 
see-saw nystagmus, periodic alternating nystagmus and convergence-induced 
pendular nystagmus
77
 
Various saccadic intrusions – inappropriate saccades hat interfere with fixation 
– may occur in patients with multiple sclerosis, including ocular flutter, 
opsoclonus,and square-wave jerks. Clinical examination of eye movements, 
with attention to dynamic properties of saccades and the vestibulo-ocular reflex, 
takes only a few minutes to perform, but may provide better information 
concerning the presence of brainstem and cerebellar involvement
78,79
. 
Disturbances of ocular motility or alignment may develop during the course of 
MS, usually result from demyelinating lesions in the brainstem that affect 
supranuclear, internuclear, nuclear, or fascicular pathways
80
. 
Frohman etal
81
 compared the accuracy of clinical detection of 
internuclearophthalmoplegia (INO) with that of quantitative infrared oculograpy 
and found good detection rates with clinical examination. 
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3.6. Optic neuritis: 
Introduction 
Optic neuritis refers to the inflammation of the optic nerves. There are many 
different causes though it is commonly associated with multiple sclerosis. Other 
causes include vascular, metabolic, hereditary, systemic disease, focal 
compressive lesions and toxins. 
In the absence of prior or concomitant neurological symptoms, then the ON 
may be referred to as idiopathic, mono-symptomatic or isolated. ON usually 
determines a moderate to severe visual impairment, followed by a complete or 
near complete clinical recovery within a few weeks.  
The process of recovery of vision has been based on two hypotheses, which do 
not exclude each other. The first suggests that axons of the optic nerve can 
maintain a normal clinical function up to a critical threshold of nerve fibers loss, 
as a result of the intrinsic structural reserve (also known as neuroaxonal 
redundancy)
 82
. The second supports the role of adaptive functional changes 
taking place at the level of striate and extra-striate visual cortical areas. The 
repair and remyelination process has been related to sodium influx across the 
cconducting axon in recent studies by Franklin  and his group  from Cambridge 
University. 
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3.7. Anatomical Classification
83
 of Optic neuritis:
 
Papillitis 
It is the inflammation of optic nerve head with evident disc swelling is the usual 
presentation. It affects the paediatric age group and is mostly bilateral. 
Retrobulbar optic neuritis 
It is the inflammation of the optic nerve beyond the lamina cribrosa. Blurred 
vision, loss of color vision and pain on eye movement is the classic triad. Pain is 
mainly attributed to the stretching of the optic nerve sheath during eye 
movements. 
3.8. Clinical classification: 
A condition causing a relatively rapid onset of visual loss with spontaneous 
recovery within 3 weeks to 3months is termed acute and those that are 
symptomatic beyond 3 months are termed chronic optic neuritis. 
Inflammation of the single nerve is termed acute unilateral ON (AON) while 
inflammation of both optic nerves is termed bilateral ON (BON). There are 2 
forms of BON depending on the time course over which the two eyes get 
affected. If the second eye develops ON within a three week to a three month 
period then the disease may be considered simultaneous (BSimON). This is 
much rarer than bilateral sequential disease (BSeqON) where the fellow eye is 
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affected at-least 3 months after the first and often after a far greater time than 
this. Sequential disease is not uncommon in MS when etiologies other than 
demyelination are frequently responsible. 
Typical acute optic neuritis (AON) 
 Young adult patient <50 years old 
 Acute or sub-acute visual loss 
 Progressive over a few days up to 2 weeks  
 Unilateral visual loss with reduced colour and contrast vision 
 Peri-ocular pain and painful eye movement 
 Normal or swollen optic disc 
 Normal macula and peripheral retina 
Features considered atypical for demyelinating optic neuritis 
 Aged <15 years or >50 years 
 No relative afferent pupillary defect 
 Aquaporin-4 (neuromyelitisoptica) antibody positivity 
 Immediate and dramatic response to steroids  
 Bilateral or chiasm involvement 
 Severity – no light perception or hand motion vision  
 Steroid dependence (worsening of vision with steroid tapering) 
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3.9. Phenotypic classification: 
SION- single isolated optic neuritis 
RION - relapsing isolated optic neuritis 
CRION- chronic relapsing inflammatory optic neuropathy (CRION), 
NMO and OSMS spectrum disorder 
MSON -multiple sclerosis associated optic neuritis 
UCON- unclassified optic neuritis (UCON) forms 
 
Other causes of AUON and BON 
 Unknown 
  Ischaemic 
  Compressive 
  Infiltrative 
  Traumatic 
  Mitochondrial 
  Hereditary 
  Toxic 
  Nutritional 
80 
 
 
3.10. Diagnostic Criteria of Optic neuritis ( ICD-10) 
1. Visual impairment due to a central or paracentral scotoma 
2. Onset of pain and onset of visual impairment separated by <4 weeks 
3. Impaired colour vision 
4. Relative afferent pupillary defect 
5. Optic disc swelling 
6. Pain resolves within 4 weeks 
7. A compressive lesion has been ruled out. 
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 4.1. Structure of the retina and optic nerve head 
 
Introduction: 
 Multiple sclerosis and its pathological process became more established from 
2006 onwards. In this process of demyelination, the evident axonal damage and 
neuronal loss was probably contributing to accumulation 
of permanent disability affecting patients and their quality of life. The concept 
of   “eye being a window to the brain” became more acceptable as retina was 
considered unique. Unique, because the retinal ganglion and axons were not 
only devoid of the myelin sheath, but also was easily visualised for assessment 
of changes.  
The unmyelinated nerve fiber seemed a perfect pitch to study the process of 
neurodegeneration, neuroprotection, and potentially even neuro- restoration
84
. 
 
 
4.2. Structure of retina: The anatomical pitch 
The retina is a multi-layered sensory tissue
85
 that lines the back of the eye, in 
front of the choroid and sclera and form the starting point for receiving and 
processing the information. It contains millions of photoreceptors that capture 
light rays and convert them into electrical impulses. These impulses travel along 
the optic nerve to the brain where they are turned into images.  
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There are two types of photoreceptors in the retina: rods and cones.  
Cones: The retina contains approximately 6 million cones. The cones are 
contained in the macula, the portion of the retina responsible for central vision. 
They are most densely packed within the fovea, the very centre portion of the 
macula. Cones function best in bright light and allow us to appreciate colour.  
Rods: There are approximately 125 million rods. They are spread throughout 
the peripheral retina and function best in dim lighting. The rods are responsible 
for peripheral and night vision.  
Retina:  
The retina
86
 is a complex multi-layer functional unit. See Fig 4.1 
Figure 4.1: Structure of the Retina 
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Embryologically the retina develops from the optic vesicle, which 
is invaginated by the ectodermal placode. This invagination gives rise to the 
multi layered inner neuro sensory retina and a monolayer of outer retinal 
pigment epithelium. The hyaloid circulation supplies the embryonic retina, 
which is then taken over by the retinal artery and vein in the 5
th
 month of 
pregnancy. The final adult retina pattern is achieved at birth. The optic nerve 
becomes progressively myelinated from the proximal to the distal direction, in 
most cases stopping at the lamina cribrosa. This contributes to a normal 
transparent retina.  
Retinal layers (outer to innermost) are:  
1. Pigment epithelium (RPE)  
2. Photoreceptor with its Outer and Inner Segment Layers (OS & IS)  
3. External Limiting Membrane (ELM)  
4. Outer Nuclear Layer (ONL)  
5. Outer Plexiform Layer (EPL)  
6. Inner Nuclear Layer (INL)  
7. Inner Plexiform Layer (IPL)  
8. Ganglion Cell Layer (GCL)  
9. Nerve Fibre Layer (NFL)  
10. Internal Limiting Membrane (ILM)  
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1. The Retinal Pigment epithelium (RPE)  
The RPE is made up of cuboidal cells, which contain the two pigments, melanin 
and lipofuscin. This layer is firmly attached to the choroid through the Bruch's 
membrane.  
 
The functions of RPE are:  
– Remove water and maintain ionic microenvironment  
– Nourish the outer parts of the retina  
– Phagocytose detached discs from the rod and cone outer              
segments. Shed discs from the outer rod segment are enclosed by delicate 
cytoplasmic extensions of the pigment epithelium (PE) and later broken down.  
 
2.  Photoreceptor outer and inner segment layers (OS & IS)  
 
Cones and rods form the vital layer, cones functioning during the day, assisting 
colour vision and rods assisting in dark adaptation and night vision. Cones are 
highly concentrated in the fovea of the macular area and aid central vision. Rods 
density is highest approximately 20degrees outside the fovea and serve high 
acuity for peripheral vision.  
Both the outer segment and inner segment of the rods and the cones are 
connected through the cilium and forms a transmission channel. The outer 
segments are composed of approximately 2000 discs stacked upon each 
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other. They contain visual pigment proteins, Rods containing 
Rhodopsin and cones containing Opsin tuned to long, medium and short 
wavelengths. It must be remembered that there is an age related receptor  
loss in the retina in normal individuals and this loss is accelerated in 
pathological conditions.  
  
3. External Limiting Membrane  
This is not a true membrane but is made up of an array of desmosomal contacts 
between Muller fibres and receptor cells, producing a pattern of netting. The 
Muller cells have their nucleus in the inner nuclear layer. They are large 
complex neuroglial cells stretching from ILM to just beyond ELM. Muller cells 
plays importance in breakdown of glutamate, providing an environment of 
homeostasis of the ionic micro-environment and neuronal survival.  
  
4. Outer nuclear layer (ONL)  
The ONL is mainly composed of the cell bodies of the rods and the cones with 
their nuclei and cytoplasm .The Rod nuclei are round/oval while the Cone 
nuclei are oval.   
 
5. Outer plexiform layer (OPL)  
OPL is made of axons of the rods and cones. They contact processes from 
the bipolar and horizontal cells that are also found in this layer. The synaptic  
87 
 
endings of the rods and cones are known 
as spherules and pedicles respectively. There are two main types of cone to 
bipolar cell contact, Synaptic Ribbon Synapses and Basal (or Flat) junctions’ 
contacts. Horizontal cells have much wider spread of processes and contact 
more photoreceptors than bipolar cells and mediate lateral interactions. Bipolar 
cells convey visual signals vertically from outer to inner plexiform layer.  
  
6. Inner Nuclear Layer (INL)  
• Horizontal cells, Muller cells, Bipolar cells, interplexiform cells 
and amacrine cells all have their nuclei in this layer. This layer is thickest in the 
fovea, thinning towards the ora serrata.  
 
7. Inner Plexiform Layer (IPL)  
The IPL is thicker than outer plexiform layer (18-36μ) as at this layer 
the second and third order neurons of the retina meet. In this layer, 
bipolar, amacrine, inter plexiform and ganglion cells form synapses. Bipolar 
cells release neurotransmitter, glutamate. They synapse 
with amacrine cell processes and ganglion cell dendrites. Amacrine cells inter-
relate adjacent areas of retina that conduction can be both directions suggesting 
that a local feedback system exists.  
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8. Ganglion cell layer (GCL)  
 This layer is 1-2 cells thick (10-20 μ) except at macular region where it 
thickens to 80 μ or more  
There are 3 major types of ganglion cell:  
a) Midget – Narrow dendrite tree -70% of all ganglion cells in central retina  
b) Parasol – Vary in size and shape – more common in peripheral retina and 
contribute to 10% of all ganglion cells  
C) Small bi-stratified – receive input from blue cone and bipolar cells – 
about 10%  
 
9. Retinal Nerve Fibre Layer (RNFL)  
  
This layer is 20-30μ at the optic disc and consists of the axons of ganglion cells, 
which radiate towards the optic nerve head in characteristic fashion. At this 
point they will form the optic nerve and become myelinated at lamina cribosa.  
  
10. Inner Limiting Membrane (ILM)  
The ILM is 1-2microns thick and very different from External Limiting 
Membrane. It is absent at the optic disc  
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4.3. Retinal Modifications  
 FOVEA 
The main mentionable modification of the retina
86
 is the very centre of the 
retina called fovea.  
At the fovea, the layers of the retina are excavated. The foveola is the most 
central part of the fovea and is completely rod and blue cone free. 
Approximately 10,000 are found at the foveola. The foveal pit acts as a mirror 
and one can see the reflex from it when using an ophthalmoscope. Neither 
the choriocapillaries nor the RPE are modified at the fovea. The cones at 
the foveola are much longer and thinner than elsewhere. The smaller diameter 
of foveal cones allows more of them per unit area give better resolution. A 
yellow pigment, Xanthophyll acts as a yellow filter absorbing blue light and 
making this area blue blind  
 
Optic nerve head (ONH)  
The optic nerve head is the beginning of the optic nerve and forms a primary 
portal of collecting visual information from the retina to the brain. The nerve 
also provides an entry and exit point into the eye for the central retinal artery 
and central retinal vein that provides nourishment for the superficial layers of 
the retina.  
The ONH is composed of the axons of ganglion cells in the retina. 
Approximately 1.2 million axons converge to form the optic nerve head that 
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exits the eye through a sieve-like structure in the sclera called the 
lamina cribrosa. There are no photoreceptors at the optic nerve head, and so it 
projects as a physiological blind spot. Ordinarily, we do not notice this blind 
patch in our vision owing to it overlapping with an area of normal sight in the 
fellow eye, and the tendency of our visual system to fill in gaps, rather than 
perceive them as black patches. Within the retina the axons pass naked along its 
surface, whereas after exiting the eye they become enveloped in myelin sheaths 
so as to promote the propagation of electrical signals. If the axons were 
myelinated within the retina they would appear white and prevent light from 
passing to the underlying photoreceptors. Viewed en-face the optic nerve head 
is seen as a circular disc with a small depression in the centre referred to as the 
optic cup, to contrast it with the surrounding neural tissue that is referred to as 
the neuroretinal rim. The cup-to-disc ratio is important clinically because its 
increase in the cup disc ratio indicates death of ganglion cells  
  
4.4. Beneath the retina: 
Beneath the retina, resting on the retinal pigment epithelium is the choroid. 
Choroid is a highly vascular layer and forms the middle coat (tunic) of the eye. 
It extends from the margins of the optic nerve to the pars plana, where it 
continues anteriorly, becoming the ciliary body.  
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Histologically, the structure of the choroid is generally divided into four layers 
(classified in order of furthest away from the retina to closest): 
 Haller's layer - outermost layer, consisting of larger diameter blood 
vessels 
 Sattler's layer - layer of medium diameter blood vessels 
 Choriocapillaries - layer of capillaries, and 
 Bruch's membrane - innermost layer of the choroid. This forms the 
Bruch’s RPE complex that is the outer retinal barrier and plays a major 
role in autoimmune diseases. 
Interestingly choroid is embryologically similar to the choroid plexus and thus 
study of choroid, is an area of interest in this research project. 
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5.1. Structural assessment: “The more than meets the Eye”  
Multiple sclerosis is a progressive disease with accumulation of disability over a 
period of time. There is a process of demyelination compounded by axonal 
degeneration leading to irreversible damage. 
Clinical assessment and clues from MRI have been used until date to study the 
rate of progression. MRI is helpful to determine activity and lesion load. On the 
contrary there is an element of clinical–radiological disassociation that means 
that a patient may be asymptomatic, even with multiple lesions in the brain and 
vice versa. 
The only part of the brain that can be visualised is the retina and optic nerve, 
thus, making eye “a window to the brain”. With advent of OCT, the visualised 
part of the brain can be quantified. This in-turn helps to determine rate of 
progression, response to disease modifying treatment and overall generate a 
model of neurodegeneration in multiple sclerosis. 
Above all, the OCT is a non-invasive investigative technique and takes only a 1-
2 minute to perform the scan. The principle of coherence interferometry means 
that there is no radiation to the patient. 
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5.2. Optical Coherence Tomography (OCT)  
 “A window into the mechanisms of multiple sclerosis”   
In 1851, Von Helmholtz
87
 introduced the use of hand –held ophthalmoscope to 
visualise the retina and optic nerve head. In 1974, Frisén and Hoyt 
88
reported 
the thinning of retinal nerve fiber using the red free filter in the 
Ophthalmoscope .In the recent years quantitative ophthalmoscopes that can be 
used efficiently and objectively to measure changes in structural architecture 
within the retina has gained importance.  
Quantitative ophthalmoscopes in current use are  
 Optical Coherence Tomography (OCT)  
 Heidelberg Retinal Tomography (HRT)  
 Scanning Laser Polarimetry (SLP) with variable corneal           
compensation (GDx -VCC)  
 
5.3. The advent of OCT:  
OCT was first reported by Huang-et-al. In 1991
89 
In-vivo retinal imaging was first demonstrated in 199390, 91 
Early studies in 1995 provided the first demonstration of OCT imaging of the 
normal retina
92.
 
Spectral domain and high speed and high resolution OCT was reported in 2002 
and 2003
93, 94, 95 
OCT became commercially available in 2006.  
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5.4. Principle of OCT: 
The principle of OCT is white light or low coherence interferometer. The 
optical set up typically consists of an interferometer (Fig5.1, typically 
Michelson type). Light is split into and recombined from reference and sample 
arm, respectively. Assembling a collection of neighboring A-scans produces a 
cross-sectional image.  
 
Figure 5.1: Principle of Spectral domain OCT. Components include: low coherence source 
(LCS), beamsplitter (BS), reference mirror (REF), sample (SMP), diffraction grating (DG) 
and full-field detector (CAM) acting as a spectrometer, and digital signal processing (DSP) 
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5.5. Spectral domain OCT (Spectralis): SD-OCT extracts spectral information 
by distributing different optical frequencies onto a detector stripe through a 
dispersive element. Thereby the information of the full depth scan can be 
acquired within a single exposure. The volumetric image is then constructed 
from a collection of B-scans. There are three major types of volumetric images 
used in OCT imaging: 
 Rectangular, or raster volume scan: A series of parallel B-scans  
 Radial volume scan: A series of B-scans at regular angular intervals  
 Annular volume scan: A series of B-scans forming concentric rings 
 
Figure 5.2, Figure 5.3 and Figure 5.4 shows the histological retina to correlate 
with findings on Ocular Coherence Tomography. 
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Figure 5.2: Light microscopic appearance of human retina  
 
Figure 5.3: Layers of retina and choroid on OCT ( Heidelberg) 
 
 
Figure 5.4: Close inspection reveals four reflective bands on OCT 
1=external limiting membrane, 2=Ellipsoid layer, 3=Inter-digitation zone, 
4=Retinal pigment epithelium ( Heidelberg) 
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1) The external limiting membrane band (ELM) is located at the boundary 
between the cell bodies (nuclei) and the inner segments of the 
photoreceptors, and comprises clusters of junctional complexes between 
the Muller cells and the photoreceptors. 
 
2)  The ellipsoid zone (EZ), which was previously referred as the 
photoreceptor inner segment/outer segment (IS/OS) junction, formed 
mainly by mitochondria within the ellipsoid layer of the outer portion of 
the inner segments of the photoreceptors. In a normal fovea, the distance 
from the EZ line to the ELM is shorter than that from the EZ line to the 
RPE. 
 
3)  The interdigitation zone (IZ) corresponds to the contact cylinder 
represented by the apices of the RPE cells that encase part of the cone 
outer segments. This layer was previously referred to as cone outer 
segment tips (COST) or rod outer segment tips (ROST), and it is not 
always distinguishable from the underlying RPE layer, even in normal 
subjects. Although this band is called Verhoeff membrane by Verhoeff as 
an anatomical structure girdling RPE cells, now known as junctional 
complexes between RPE cells.  
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4)  The retinal pigment epithelial band is formed by the RPE and Bruch’s 
membrane (indistinguishable from each other in a normal state using 
current SD-OCT systems). In the fovea, this band is thicker, which 
indicates that choroidal structures may also contribute to the hyper-
reflectivity of the RPE band at this location. 
 
5.6. OCT of the Choroid  
 
Enhanced Depth Imaging (EDI)-OCT :Imaging beyond the RPE  
 
 EDI-OCT is a new imaging modality to enable high-resolution 
imaging of the choroid and lamina cribrosa.  
 It is noninvasive, reproducible and comfortable to patients as 
standard OCT. 
100 
 
 
Figure 5.5: Enhanced depth imaging showing clear definition of choroid (below) 
compared to poor definition of choroid (above) 
 
Figure 5.6: Principle of EDI OCT ( Heidelberg, Germany) 
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               Functional assessment of visual system 
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6.1. Function of visual system 
Introduction 
Visual dysfunction is one of the most common clinical manifestations of 
multiple sclerosis (MS).  MS clinical trials did not include visual outcomes a 
decade ago. Snellen’s visual acuity chart was the common visual testing at that 
time and the lack of change of vision parameters with concurrent change in 
EDSS might be one of the justifiable reasons. The Optic neuritis treatment trial 
(ONTT)
 96, 97
 set the scene for the current trend in assessment of visual pathway.  
6.2. Senses of the visual system 
The stimulation of retina results in four types of sensation -light sense, form 
sense, colour and contrast sense. 
a) Form Sense 
Form sense is a faculty that enables us to perceive the shapes of the objects. The 
ability to perceive this is called visual acuity as termed by Donders in 1861. 
Visual acuity includes sharpness of retinal focus and ability of interpretive focus 
in the brain. The sharpness of focus is mainly dictated by the function of the 
cones in the fovea. The brain has interpretive components such as recognition of 
objects, resolution of 2 spatially separated targets and alignment. 
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Resolution is the ability to resolve two spatial separated target points. It 
normally subtends a visual angle of 1 degree at the nodal point. This equates to 
0.0004mm size of the object which is the size of the foveal cones
98
. This is 
ordinary visual acuity; a function of the cones. The ability to resolve 2  line 
segments is termed as hyperacuity or vernier acuity. The visual angle is much 
smaller than the 1 degree and the processing most probably takes place in the 
visual cortex. 
b) Contrast sense 
Contrast sensitivity is a measure of the ability to discern between luminance of 
different levels in a static image. Contrast sensitivity varies between individuals, 
reaching a maximum at approximately 20 years of age, and at spatial 
frequencies of about 2–5 cycles per degree. In-addition it can decline with age 
and also due to other factors such as cataracts, glaucoma, optic nerve disease 
and diabetic retinopathy
98. 
c) Colour sense 
It is the ability to distinguish between colour and colour tones. There are three 
primary colours, red, green and blue. Colour is best appreciated in bright light 
whereas they appear grey in dark, a phenomenon called Purkinje’s shift. 
Perception of colour begins in the cones, which contains pigments three 
different spectral sensitivity. This results in tri-chromatic colour vision. The 
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Opsins (photo pigments) present in the L and M cones are encoded on the X 
chromosome; defective encoding of these leads to the two most common forms 
of colour blindness
100
.The OPN1LW gene, which codes for the Opsin present in 
the L cones, is highly polymorphic (a recent study by Verrelli and Tishkoff 
found 85 variants in a sample of 236 men)
101
. A very small percentage of 
women may have an extra type of colour receptor because they have different 
alleles for the gene for the L opsin on each X chromosome. X chromosome 
inactivation means that only one Opsin is expressed in each cone cell, and some 
women may therefore show a degree of tetra-chromatic colour vision.
102 
Variations in OPN1MW, which codes the opsin expressed in M cones, appear to 
be rare, and the observed variants have no effect on spectral sensitivity. 
6.3. Cone cells in the human eye
103,104 
Name Cone type Range Peak 
S Β 400–500 nm 420–440 nm 
M Γ 450–630 nm 534–555 nm 
L Ρ 500–700 nm 564–580 nm 
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6.4.Theories of color vision 
Tri-chromatic theory of colour vision 
Thomas Young in 1802 and thereafter Hermann Von Helmholtz in 1852 
proposed that all human vision occurred through the combination of sensitivity 
to red, green, and blue. This theory came to be known as the Young-Helmholtz 
trichromatic theory of colour vision. The finding that there are three types of 
colour-sensitive cone receptors in the retina supported the three-colour 
theory
105
. One set of receptors is sensitive to long wavelengths such as red, one 
to medium wavelengths such as green, and one is sensitive to short wavelengths 
such as blue. The basic idea was that the eye responded to three primary 
colours, and combining the three primary colours of additive colour mixing 
formed all the other colours. 
Opponent Processing Theory of Colour Vision 
As the trichromatic theory did not explain it all, Ewald Herring, the father of the 
opponent processes theory came up with some interesting thoughts. Firstly, he 
noted that there are certain pairs of colours one never sees together at the same 
place and at the same time such as one does not see reddish greens or yellowish 
blues. Secondly, he noted a distinct pattern of colour of the after images we see; 
for example if one looks at a unique red patch for about a minute and then 
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switches the gaze to a homogeneous white area they will see a greenish patch in 
the white area. 
Herring hypothesized that tri-chromatic signals from the cones fed into 
subsequent neural stages and exhibited two major opponent classes of 
processing.  
1. Spectrally opponent processes, which were red vs. green and yellow vs. 
blue.  
2.  Spectrally non-opponent processes, which were black vs. white. This 
opponent process model lay relatively dormant for many years until a pair 
of visual scientists working at Eastman Kodak at the time, conceived of a 
method for quantitatively measuring the opponent processes responses. 
Leo Hurvich and Dorothea Jameson invented the hue cancellation method 
to psychophysically evaluate the opponent processing nature of colour 
vision. 
Due in large measure to the efforts of Hurvich and Jameson the opponent 
processes theory attained a central position shared with the trichromatic theory. 
Consequently, with the quantitative data provided by the psychophysics and 
direct neurophysiological responses provided by electrophysiology opponent 
processing is no longer questioned. Based on the existence of colour 
afterimages, Ewald Herring proposed the opponent process theory
106
 of colour 
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vision in 1878. He suggested that colour vision occurred in three channels 
where "opposite" colours (called complementary colours) are in a form of 
competition. For example, red and green are complementary colours. When you 
stare at something red, your redness detectors are worn out or fatigued. Their 
opponents, the green receptors, gain the upper hand, and you see a green after-
image after staring at a red dot. 
6.5. Men and colour blindness: 
Colour-blind people usually have a complete (achromatopsia) or incomplete 
absence (dyschromatopsia) of colour. There might be one or more missing cone 
types: red-sensitive, green-sensitive, or blue sensitive. The result is a disorder in 
one or both colour channels.  
The most common type of colour blindness is red/green colour blindness. 
Genetic studies show this type of colour blindness is usually caused by a 
defective gene on the X chromosome. If this gene is defective, women (having 
two X chromosomes) are "protected" by a duplicate copy of the gene on the 
other X chromosome. Males (having one X and one Y chromosome) do not 
have the extra copy, so red/green colour blindness is about 20 times more 
common in men than in women 
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6.6. Monochromat 
A person with no colour sensitive pigments, therefore no colour vision, is called 
a monochromat (one-color person). To such a person, the world looks like a 
black-and-white TV picture. Colours are shades of grey. 
6.7. Dichromat 
A person with a defect in one channel-either the red/green or yellow/blue 
channel-is called a dichromat. Both colours in a channel are affected, so if the 
person cannot distinguish red that same person cannot distinguish green. A 
person who cannot see blue as a distinct colour will also not see yellow as a 
distinct colour. 
6.8. Tri-chromat 
People with normal colour vision use all three channels (black/ white, red/green, 
and yellow/blue) and are called tri-chromats. 
6.9. Testing of visual sense in Multiple Sclerosis 
6.10. Form and contrast sense 
Vision is commonly tested using Snellen’s charts. Ophthalmologist, Herman 
Snellen in 1862, developed the chart. The common Snellen chart is printed with 
eleven lines of block letters. The size of the letter drops from being large in the 
109 
 
first line and being small in the very last line. The principle behind the sizing of 
the letter is based on the visual angle it subtends on the fovea, whole letter 
subtends an angle of 5 degree and each segment in the
107
 letter subtends an 
angle of 1 degree at the specified viewing distance. 
Normally the test is taken at a distance of 6meters or 20 feet away. The smallest 
row that a person can read is the actual visual acuity of the patient. The test can 
further be tested with pinhole in front of the eye to rule out media opacity and 
refractive error. The letters are designed opto-types and comply with simple 
geometry. The thickness of the lines equals the thickness of the white spaces 
between lines and the thickness of the gap in the letter "C". The height and 
width of the optotype (letter) is five times the thickness of the line. Only the ten 
Sloan letters C, D, E, F, L, N, O, P, T, Z are used in the common Snellen’s 
chart.  
Visual acuity = Distance at which test is made / distance at which the smallest 
optotype identified subtends an angle of 5 arc minutes. 
Patients unable to read the chart at 6 m are asked to read it at 3m and 1m. For 
patients unable to read the letters on the closer placed charts are asked to count 
fingers close to face. 
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 Figure 6.1: Snellen’s charts 
 
Limitations of Snellen’s chart: 
* Tests only form sense with no indication of contrast, colour, depth perception 
or field of vision. 
* Crowding phenomenon 
* Forced choice option 
* Does not measure quality of vision 
* Overall a poor measure of vision 
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6.11. Introduction of  Contrast charts ( LogMAR) in Multiple sclerosis 
In the late 1990’s, the National Multiple Sclerosis Society Clinical Outcomes 
Assessment Task Force developed the MS Functional Composite (MSFC) in 
response to the need for more sensitive neurological outcome scale
108, 109
. 
Snellen’s high-contrast visual acuity (VA) did not change over time or 
demonstrate concurrent changes with EDSS scores. Contrast sensitivity, as 
tested by line gratings and letter charts in MS and by Pelli-Robson charts in the 
Optic Neuritis Treatment Trial (ONTT), had been shown to be a sensitive 
measure of afferent visual function, even among patient with Snellen’s acuities 
of 20/20 or better
110.
 Importantly, measures of low-contrast vision are predictive 
of “real-world” visual tasks such as reading rate, facial recognition, and driving 
.Hence was the introduction of Sloan’s contrast charts to the clinical scenario in 
MS. 
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6.11a.Logarithmic Sloan  contrast charts 
The charts of the low-contrast (gray letters on white) charts are “cousin” of the 
ETDRS (early treatment of diabetic retinopathy study) high-contrast VA charts 
used in ophthalmology clinical trials (Figure 6.2). Sloan charts have a 
standardized format based on the ETDRS VA charts. Three contrast levels have 
been used in MS trials and research studies, including 100% (high-contrast, 
used to measure VA as a descriptor of the study cohorts), 2.5%, and 1.25% 
(lightest contrast level). Charts are scored letter by letter, and numbers of letters 
identified correctly constitute the score for each chart. 
Figure 6.2: LogMAR chart 
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Most recently, visual improvement and loss by the low-contrast acuity chart has 
been defined as a 7-letter change in score, while 5-letter changes in high-
contrast VA are now considered clinically significant for patients with good 
visual acuity
111
. This threshold represents a change that exceeds that which 
would be expected from repeated testing when there was no real change, and to 
correlate with RNFL axonal loss in patients with MS.
112 
Figure 6.3:  Sloan chart 2.5%  
 
 
 
 
 
 
Illumination is a very crucial part in contrast vision testing. Without a constant 
and standardized illumination, contrast charts may be inaccurate. Precision 
Vision Contrast Charts are recommended with the use of our retro illumination 
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cabinets. With this illumination, contrast levels are more accurate and testing is 
more reliable. Controlled illumination is crucial for achieving accurate contrast 
sensitivity results. 
 
6.12. Colour vision testing in Multiple sclerosis 
The Ishihara Pseudo isochromatic charts have in countless times in the past 
tested colour vision. With the invent of the sensitive Anomaloscope , the 
Ishihara chart has been known to be a vague indication of colour deficiencies. 
One of the pseudo isochromatic charts which over performs the anomaloscope 
is the Richmond HRR chart, 4
th
 edition.  
Sixty years ago LeGrand Hardy, Gertrude Rand, and M. Catherine Rittler  
commenced development of a colour vision test that later was made 
commercially available under the name “HRR Pseudoisochromatic Plates” 
(Hardy et al., 1954) .Based on a fail criterion of three errors on the 
transformation and vanishing plates, the sensitivity of the Ishihara test is around 
99% and the specificity is 94%the sensitivity of the Richmond HRR test has 
been reported to be 100% sensitive  and the specificity to be 96%. 
 
 
Abnormalities in colour vision are common in patients with multiple sclerosis 
(MS), especially after optic neuritis (ON),even though acquired 
dyschromatopsia is also well documented in MS patients
113
 without ON. 
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Colour deficits can be detected in 70% of MS patients without a history of 
previous ON by using the Farnsworth-Munsell (FM)-100 tests. 
 
Although the mechanisms involved in colour vision impairment are not  
completely understood
114
, the result of functional tests of colour vision suggests 
that impaired colour vision is produced primarily by injury to the anterior visual 
pathway
115
 rather than to postchiasmatic or posterior visual pathway structures. 
 
6.13. Testing of colour on HRR charts 
The test chart is held on a rack of illuminator about 30 inches from the patients. 
Any source of extraneous light should be turned down to avoid false 
interpretations. The test charts have 24 plates in total. 1-4 are test charts, 5-10 
are screening charts and 11-24 are testing charts .See test reporting chart below. 
.Six plates (screening series) present the most difficult yellow, blue, red, and 
green colours and separate normal from defectives. Subsequent 14 plates 
diagnose as to the extent (mild, medium or strong) and type of defect (protan, 
deutan, tritan).  
 
 
 
 
 
116 
 
Figure 6.4: HRR chart 
6.14. 
Field of vision 
The VF is a three dimensional cone (Traquair's island of vision), with its apex at 
the nodal point of the eye, and its base at infinity (or at whatever distance we 
plot it by a perimeter screen or bowl) (Figure 6.5). The purpose of visual field 
testing is to define the topography of the island of vision to recognize any 
variation from normal. 
Figure 6.5: Hill of vision 
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The plotted VF (the base of the cone) extends for approximately 60 degrees 
superior, inferior, and nasal and 100 degrees temporally. For practical purposes, 
the VF plot may be divided into three major parts: the central 30 degrees, the 
peripheral field (from 30 to 60 degrees), and the temporal crescent (Figure 6.6). 
 
Figure 6.6: Field of temporal vision 
The visual field test is designed to assess the sensitivity of the eye as well as the 
extent of the peripheral vision.  
The patients chin is placed on a chin-rest to start a series of flashing lights on a 
bowl-shaped screen. The lights may vary in brightness and will appear in 
different positions in your field of view. Typically a 24-2 SITA test takes about 
5 minutes per eye and a 30-2 about 7 minutes per eye. Full threshold tests can 
take up to twice as long.  
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6.15. Humphrey SITA and Full Threshold Testing 
The Humphrey Visual Field is standard tests that allow us to look for defects in 
the sensitivity of the eye.  
Threshold Visual Fields: 
Threshold testing of visual fields identifies the limit of the sensitivity of the eye 
at programmed locations in the visual field.  
The most common Humphrey test is the 24-2, which tests the central 24 degrees 
of vision. The Humphrey 10-2 test permits monitoring of patients with very 
restricted fields and the 30-2 has more peripheral points. The following 
strategies are available for the 24-2, 10-2, 30-2 tests and 50-2 
 
Full Threshold - makes the least assumptions about the patient's vision. The 
brightness of the stimulus is varied at each location in order to find the threshold 
value. The results are based on the last point seen at each location, so patient 
fatigue may affect the accuracy. 
 
SITA Standard (Swedish Interactive Threshold Algorithm). With the benefit of 
research into visual fields, the SITA test is able to make predictions of threshold 
values by analysing the patient's previous responses. By analysing the data in 
this way the length of the test is reduced, often less than half the length of a 
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similar full-threshold test. The results are calculated using all of the data 
collected, so errors may be identified and corrected automatically. 
 
SITA Fast - the fastest threshold test. Best used with reliable subjects. 
Stimulus Size - Full threshold tests may be carried out using different stimulus 
sizes. These equate to the stimulus sizes used by the Goldmann Perimeter. 
Humphrey tests are normally carried out with stimulus size III, but patients with 
poor vision may be tested with a size V stimulus. Please note the SITA tests are 
only possible with a size III stimulus. 
 
Stimulus Colour - the Humphrey test is normally carried out using a white 
stimulus against a white background. However, the stimulus colour may be 
changed when monitoring colour dependent changes.  
Progressor Visual Field Analysis 
Using the Institute of Ophthalmology's Progressor software, we are able to 
monitor progression of visual fields using linear regression analysis. The 
software is able to identify progressing points from a series of Humphrey 24-2 
Full Threshold or SITA examinations and marks them according to clinical 
significance.  
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6.16. The Humphrey printout 
The test results (with or without the statistical analysis) are usually printed on 
one sheet called the printout (Figure 6.7). When examining the test results, the 
two printouts (right eye print out in your right hand facing your right eye, and 
left eye printout in your left hand facing your left eye), and examination is done 
together. 
Figure 6.7: Humphrey’s visual field print out
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6.17. Patient’s data and test parameters (A& B on Fig 6.7) 
These are at the top of the printout. 
 The first priority is to make sure that those fields belong to the patient in 
question, and that the specific program requested has been used. 
 The date of birth has to be correct (for comparison with range of normal 
values for age). A pupil diameter of at least 2.5 mm is essential to avoid 
overall depression of test values. Finally, using near correction lenses, 
and/or high astigmatic error correction lenses is strongly advisable to help 
the patient appreciation of the test targets. A frameless lens may be best 
suited for that, but other lenses could be used and allowance for any rim 
artefacts made during interpretation. 
Reliability indices 
The second priority is to check the patient' performance (reliability). These 
parameters are printed at the top left hand side of the print out in the Humphrey 
perimeter. 
Fixation loss: Normally this is between 0 to 2%. If the loss exceeds 20%, this is 
generally considered as poor reliability. However, it may also be an indicator of 
advanced glaucoma with an abnormally large blind spot. Other indicators of 
advanced glaucoma should be looked up first, before disqualifying the test 
results as unreliable based on poor fixation. 
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 False-positive or false-negative responses. Scores in excess of 20-30% 
indicate a test of questionable reliability 
The grey scale (D on figure 6.7) 
 This is a graphic representation of the recorded threshold sensitivities in 
the numeric scale. Regions of decreased sensitivities are displayed in 
darker tones. The grey scale plot is very useful for displaying patterns of 
loss (nerve fibre layer defects versus neurological defects) and thus 
should be inspected first. When looking for such patterns, both right and 
left grey scales should be inspected together. If any visual field defect 
related to pathology of the visual pathway distal to the lamina cribrosa is 
revealed, then attention is directed to other tests to examine the rest of the 
visual pathway. 
 It is also a very useful tool in explaining – to the patient and family – the 
stage of the disease and its progress over time. 
 
The numeric scale(C on figure 6.7) 
This is the main test result. It shows the retinal sensitivities at the different test 
locations, expressed in Decibels (dB).  
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The numbers expressed in the numeric scale may be looked at as heights, and 
with the higher values in the centre, and the least values at the periphery, one 
can ‘see’ the centre of the hill of vision in a three dimensional way. 
6.18. Statistical analysis of test results 
Inclusion of statistical analysis software is the reason for the widespread 
popularity of static perimetry. Computers can store a huge amount of numbers 
and use them to look for patterns, compare them with stored database, and 
perform all kinds of analysis on them. 
The Stat-PAC software is a commonly used analysis tool in both Humphrey. It 
is used to look at suspicious clusters of numbers, analyse them, and monitor 
their change over time. 
Total deviation plot (E&F on figure 6.7) 
 These numbers show the difference (in dB) between the test results and 
the normal values expected for the patient's age group. 0 dB = no 
difference (normal), while −13 dB = large depression from normal value 
(see the total deviation plot in Figure 6.7). The true value of the defect in 
this instance should be −17 dB, but the computer allows for a variability 
of −4 dB. 
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 This is in fact a plot of the probability of each point change being normal. 
If less than 0.5% (indicated by the solid black squares), then the point 
change is highly unlikely to be normal. 
Pattern deviation plot (G& H on figure 6.7) 
This particular analysis tool is helpful for detecting visual field defects 
(scotomata) in the presence of media opacities, such as cataract. It does this by 
looking at the overall sensitivity changes in the hill of vision (the ‘pattern’ here 
is the conical shape of the hill of vision). If there is an overall depression (all 
test values are reduced from normal due to cataract), then it will subtract this 
value from all test points, leaving behind clustered field loss (localised defects), 
which may be due to glaucoma. 
‘Inclusion of statistical analysis software is the reason for the widespread 
popularity of static perimetry’ 
Global indices ( J&I on figure 6.7) 
These numbers represent mathematical summaries of all the sensitivity values 
produced by the test. They are useful tools for having a quick idea about the 
entire field, and sequentially compare test results for the same eye (change 
analysis). Looking at them however, does not replace examining other test data 
in detail. Note that the newer SITA (Swedish Interactive Threshold Algorithm) 
software has just a pattern standard deviation.  
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Mean deviation 
This number reflects the overall depression (deviation from normal values) of 
the field. All the obtained values of the test are added, and divided on the 
number of test locations. This gives the mean value of the test. The same is 
done for the normal expected values stored in the computer database. The 
difference between the 2 values represents the MD. Normally it should not 
exceed −2 dB. If the MD is significantly outside the normal, then a P value is 
assigned to it. 
Pattern standard deviation 
For practical purposes, the pattern standard deviation (PSD) reflects the degree 
of departure (difference) of the measured VF pattern (shape) from the normal 
hill of vision. A small PSD reflects a smooth uniform hill of vision (Figure 6.9), 
while a large PSD value reflects an irregular hill of vision (Figure 6.8). 
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Figure 6.8: Hill of vision on Pattern standard deviation (steep) 
 
The pattern standard deviation (PSD) is the difference between the expected 
data (the straight line at the top) and the patient's own data (the irregular line 
beneath it). Here, the sum of the differences is 38, which, when divided by 
number of test locations, yields 5.4. This reflects an irregular hill of vision. 
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Figure 6.9: Hill of vision on PSD (smooth) 
 
The sum of the differences is here is 1.7, a much smaller number, which reflects 
a much smoother hill of vision with a more normal pattern to the visual field. 
6.19 The change analysis printout 
This is a simple graphic representation of summaries of sequential VF tests for 
the same eye using all global indices. It helps to evaluate progression (or 
stability). Care should be taken when using change analysis, because it requires 
many reliable fields (at least 4 excluding the first one to avoid learning 
mistakes). To compare results from a small number of fields, one can use the 
‘Multiple field’s printout’, to visually track changes between the tests in 
question. The change analysis printout allows us to track changes over time. 
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Figure 6.10: Progressive field analysis
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The hemi-field analysis 
This software allows comparison of VF defects across the horizontal axis 
(looking for – and comparing – nasal steps). As such it alerts you to the need to 
re-examine the printed results, looking for such differences. The three important 
responses to look for are: 
1. Within normal limits (no differences) 
2. Borderline (early differences) 
3. Outside normal limits (obvious differences between the upper and lower 
halves of the field) 
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Chapter 7: Methodology 
Introduction 
This project aims to introduce a number of advancements in the development of 
visual function outcomes in MS as well as OCT as a novel technology that 
enables objective analysis of the processes of neurodegeneration. In addition, 
we present representative group data from visual function, OCT measures, and 
visual field indices in patients with MS, ON, and disease-free control (Table 1).  
These data may be used to provide initial reference values and should be viewed 
in the context of 1) the continually-evolving field of vision in MS; 2) the 
potential challenge inherent in applying group data to individual patients; and 3) 
the perspective that even the small observed differences in mean OCT values 
have been shown to correlate with clinically meaningful changes in visual 
function in MS patients. 
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“Eye is a window to the brain”  
Structural loss of neurons in the optic nerve/retina in MS (as measured by OCT) 
is related to loss of vision on functional visual tests and also to neuronal loss as 
measured by EDSS. 
Primary Outcome:  
a) To study the anterior visual pathway with a view to correlate structure 
with function.  
Secondary Outcome:  
b) To correlate the structure of anterior visual pathway with neurological 
function (EDSS, QOL) 
 Overall this may throw light on visual outcomes as a marker for early 
diagnosis, disease progression and monitoring the response in patients treated 
with disease modifying therapy (DMT). 
Use of visual parameters in diagnosing and monitoring the disease in Multiple 
sclerosis is not a common practice in the United Kingdom or elsewhere. 
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Primary Objectives:  
1) To study the sensitivity and specificity of non-invasive vision tests such 
as LogMAR, colour charts and contrast sensitivity charts in diagnosis and 
monitoring treatment in relapsing remitting multiple sclerosis. Snellen’s 
visual acuity is a routine test in assessing vision in MS patients. It will be 
compared with specific visual charts such as LogMAR, HRR and contrast 
charts.  
2) To perform non-invasive eye investigations such as OCT of retina, 
choroid and optic nerve (Optical coherence Tomography)) to detect nerve 
fiber loss in the retina and optic nerve head in MS.  
Secondary Objectives:  
1) To find a correlation between visual outcome measures on OCT with 
disability outcome measures such as EDSS (Expanded disability status 
score) and QOL in Multiple Sclerosis (MS).  
2) To correlate point sensitivity on visual field with thickness of nerve fiber 
on posterior pole OCT 
3)  To compare the structural and functional visual changes in patients with 
and without optic neuritis.  
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4)  To explore if age of onset of optic neuritis correlates with visual                
outcome 
5) To evaluate the usefulness of EDI-OCT in studying the choroid. 
Methodology 
The project “Structure and function of the visual pathway in demyelinating 
optic neuropathy " was carried out in the University Hospital of North 
Staffordshire, now called the Royal Stoke University Hospital. 
The project was approved by the IRAS and peer review committee at Keele 
University. 
The study integrated work between the department of Ophthalmology and 
Neurology. Senior consultants in Ophthalmology and Neurology along with the 
senior Orthoptist monitored the activity and patient turn over. 
A total of 60 patients (120 eyes) and 25 controls (50 eyes) were included in this 
prospective case control study. Patients attending their routine Neurology 
outpatient clinic were identified 4 weeks in advance on the patient record 
system of the UHNS trust. Phone calls were made to discuss the project with the 
patient. Patient information leaflet and consent form were posted to those keen 
on being enrolled in the study.  
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On the day of the visit, patients were given time for discussion, questions and 
answers before proceeding to the actual tests. Most patients were happy to 
contribute to this research with only one patient not happy to be recruited as he 
lived very far away. The support from the Ophthalmology department to access 
the various investigative modalities was excellent which made carrying the 
project more enjoyable.  
Further, weekly meetings were held between the Prof Hawkins (PhD 
supervisor), Mr Jones and Mr Ragheb (Ophthalmology) and Prof Strange / Dr 
Ramachandran (Interest in MS and statistics) along with quarterly meetings 
with Prof Jones (Statistician).  
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Study population 
Cases:  
Patients with Relapsing remitting type of MS (RRMS) who fulfilled diagnostic 
McDonald criteria 2010 were included in the study. CIS (clinical isolated 
syndrome) and suspects were not included in the study due to lack of diagnostic 
criteria for this group. Patients with or without optic neuritis and those on DMT 
treatment were included. 
Controls: Normal volunteers  
Inclusion Criteria 
 Age:  18- 65 and able to consent 
 Diagnosis of Relapsing Remitting MS using Mc Donald’s criteria (2010) 
in patients with or without treatment, with or without optic neuritis.  
Exclusion criteria  
  Any progressive neurological disorder (other than MS), 
 Any medical condition or limiting psychiatric disease (including 
depression, bipolar and psychosis) that may interfere with the subject’s 
ability to cooperate and comply with study procedures 
   Any state of immunosuppression different from MS; 
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   Any ophthalmological causes for retinal damage different from MS or 
major difficulties for OCT evaluation such as severe refractive defects 
[myopia > −6.0D or axial eye length >26 mm; hypermetropia > 5 D; 
cylinder > 3D], optic disc drusen, cataract and glaucoma.  
  Current or previous treatment with a drug involved in toxic neuropathy, 
such as Ethambutol, Isoniazid, Linezolid, Gentamycin, Chloramphenicol, 
Vincristine, Penicillamine. 
 Recent history of acute optic neuritis (<6 months). Patients with ON 
within 6 months of the acute episode were not eligible.  
  Previous diagnosis of Diabetes Mellitus or impaired fasting glucose 
(≥126 mg/dl or ≥ 200 mg/dl after oral glucose tolerance test) 
   Inability to undergo MRI: reduced renal clearance (screening: 
GFR < 45 ml/min), history of severe hypersensitivity to gadolinium-
DTPA, claustrophobia  
  History of substance abuse in the last 5 years including alcoholism 
(>40 g/day for women and 60 g/day for men) and severe tobacco use 
(>20 cigarettes/day). Patients with acute relapses or systemic steroid 
treatment in the previous month can be included 2 months after the acute 
episode 
 Unable to position on the various testing equipment 
 Unable to consent 
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On the day patients identified and happy to be recruited were invited for 
discussion about the visual project. There was a ten-minute session for question 
and answers, which included history taking and consent process. 
Patients were invited to read the test charts, which included 
1) The 100% LogMAR contrast test chart   
2) The Sloan 2.5% and 1.25% contrast test chart 
3) HRR colour test chart, followed by 
4) Humphrey’s visual field test   
Tests 1-4 were done with appropriate corrective glasses if required. Further tests 
were in the Ophthalmic imaging rooms where patients had 
5) OCT tests to study 
a) Macula ( Fig 7.1) 
b) Optic disc 
c) Posterior pole (Fig 7.2) 
d) Choroid.  
All these tests were done in between the normal NHS workload. UHNM 
ophthalmic staff offered great deal of support during the recruitment process. 
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Controls outside the study group were tested for coefficient of variability prior 
to the start of the recruitment. 
Fig 7.1: Image of the macula and correlating OCT. 
  
Fig: 7.2 showing posterior pole and correlating OCT image.
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                                 Structure meets function 
 
 
 
                  Result 1: Evaluation of Visual function test 
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Chapter 8: Results 
8.1. Study 1: Evaluation of Visual function test in disease and control 
 
 
Introduction 
 
We methodically conducted functional assessment of visual pathway using the 
standard Snellen’s vision charts comparing with the Logarithmic minimal angle 
of resolution chart (LogMAR) and sensitive Sloan low contrast (2.5% & 1.25%) 
visual acuity charts. 
 
8.2. Methodology 
 
A total of 60 patients (mean age 48, range 32-68) and 25 controls (mean age 45, 
range 38-52) were considered for the study.  5 patients from the disease arm 
were considered un-suitable (See figure 8.1). Thus, one hundred and ten eyes 
with MS and 50 eyes, disease-free control subjects participated in a single 
testing session. There were few exceptions to the single testing process, which 
accounted for six patients, who were recalled due to poor focus and inability to 
concentrate as a part of the disease process. 
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Figure 8.1: Flow chart of patient recruitment  
 
 
 
 
 
90 patients assessed for eligibility 
60 considered suitable  
5 patients excluded from the study 
Causes for exclusion: 
claustrophobic, difficult wheel chair 
access to the various visual tests, 
fatigue, and cataract and poor 
patient cooperation. 
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Table 8.2: Baseline features of recruited candidates. 
 
 Total 
patients 
N 
Mean age 
in years 
(Range) 
Male: 
Female 
ratio 
Ethnicity RRMS SPMS 
Control 25 45 
(38-52) 
40:60 Caucasian 
100% 
0 0 
Disease 55 48 
(32-68) 
30:70 100% 
Caucasian 
55 0 
 
RRMS: Relapsing-Remitting MS; SPMS: Secondary Progressive MS;  
N= patients recruited. 
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Table 8.3:  Neurological sub-grouping of disease  
 
Median EDSS 
Disability score 
Median disease 
duration ( years) 
Patients on 
DMT 
Patients not 
on  
DMT 
ARR (relapse rate in prior 24 
months 
3.2+_ 2.8 8.2 +_ 8.4 25 (50 eyes) 30 (60 eyes) 0.4+- 0.8 
 
EDSS: Expanded Disability Status Scale; DMT: Disease modifying treatment  
ARR: Annualised Relapse Rate. 
 
Table 8.4:  Optic neuritis subgroup 
 
Total eyes  
In disease 
group  
N 
MS with 
No history 
of optic 
neuritis 
 MS-with 
history of 
optic 
neuritis 
Bilateral 
ON 
Unilateral 
ON 
Median 
Age at ON 
(years ) 
Duration of 
ON (years) 
110 eyes 65 eyes 45eyes 26 eyes 
( 13 
patients) 
19 eyes 22 years 
(18-35) 
18 years 
(10-28) 
N: number; MS: multiple sclerosis; ON: optic neuritis 
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Patients and controls underwent testing with the standard chart (Snellen’s) and 
LogMAR (100%) and Sloan 2.5%, 1.25% charts. All patients were tested for 
refraction and need for glasses. A focimeter helped to determine refraction in 
patients with existing glasses. 
 
Snellen’s chart: 
Most patients in the disease and control arm performed the test with ease. 
Results from the test charts were obtainable in all patients with no hindrance 
from patient or test factors. Overall letter score as depicted by the Table 8.5 
below showed no significant difference in the disease versus control arm. The 
optic neuritis group missed few more letters when compared to the overall 
disease group. 
Table 8.5: Snellen’s letter score in the different groups 
 Snellen’s binocular letter score 
Mean ( standard deviation) 
Control ( n= 25 patients) 56  (SD 2) 
Disease (n= 55 patients) 53 (SD 3 
Optic neuritis group( n=45 patients) 49 (SD 2) 
DMT group( n=25 patients) 53 (SD 3) 
No optic neuritis group 65 patients 53 (SD 2) 
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Distribution analysis of visual letter score charts for LogMAR and Sloan. 
 
Depicted is the distribution of letter scores derived in the disease cohort. 
 
 
Figure 8.7: distribution of data of the disease group on binocular 
LogMAR charts 
 
 
Figure 8.8: distribution of data of the disease group on binocular Sloan 
2.5%charts 
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Figure 8.9: distribution of data of the disease group on binocular Sloan 
1.25% charts 
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Figure 8.10: Box- whisker plot showing IQR for LogMAR, Sloan 2.5% and 
Sloan 1.25% charts tested uniocularly for the right eye in the disease arm. 
Y axis shows letter scores for each variable. 
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Figure 8.11: Box- whisker plot showing IQR for LogMAR, Sloan 2.5% and 
Sloan 1.25% charts tested binocularly in the diseased arm. Y axis shows 
binocular letter scores for each test chart 
X axis shows different test chart 
 
 
 
 
Vertical bars indicate inter-quartile range (25th to 75th percentile observations) 
for each median score. Lower contrast levels (%) correspond to lighter gray 
letters on the white background. Despite nearly equal scores for visual acuity 
(difference in median scores of 2 letters), greater differences were observed for 
contrast letter acuity scores at lower contrast levels, particularly 1.25% (p = 
0.0001 for all levels). These differences were noted even following correction 
of refractive error in both the MS and the control groups 
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Sloan 2.5% and 1.25% charts 
The Sloan chart is used similarly to a LogMAR chart with the same standard 
illumination and standard distance of 4 meters. The only difference is the 
contrast of letters, which decreases in the row and between the rows of letters.  
There was a highly significant difference between the 2 groups   in the 2.5% and 
1.25% letter score. See chart below (Figure 8.6) 
There was a clear struggle to read the letters on the 1.25% and 2.5% chart in the 
disease group when compared to the control arm. The struggle to read was 
worse in the 1.25% group. This has sometimes been attributed to floor lighting 
in some previous articles, though clearly this was not the case in our cohort. 
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Figure 8.6: Bar chart representing the sensitivity of different chart in the 
same subset of patient and control. (Sloan charts showing increased 
detection of patients affected with optic neuropathy in disease state) 
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Binocular testing 
8.6. Concept of binocular summation  
During the vision testing, both uniocular and binocular vision was tested. In 
our cohort, there was increase in the binocular letter scores. Binocular 
summation of acuity occurs when vision is improved under binocular viewing 
conditions (binocular score is greater than the scores for either eye alone) 
(Figure 8.12)  
 
Figure 8.12: Showing binocular summation to different vision chart 
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8.7. Concept of Binocular inhibition: 
Patients with binocular inhibition had worse binocular vision compared to the 
better eye alone. Among 55 patients with MS and 25 disease-free controls, 
binocular summation was substantial (5–7-letter increases over better eye 
acuity, 28–52% with>7 letters, P<0.001) for low-contrast acuity at the 2.5% and 
1.25% levels. For high-contrast VA, only 3.0–3.4% of patients showed similar 
degrees of summation. Increasing age (P<0.0001), greater interocular 
differences in acuity (P<0.0001), and prior history of ON (P=0.015) were 
associated with lower magnitudes of binocular summation; in fact, 2 of these 
patients had binocular inhibition.  This mainly was linked to the severity of 
optic neuritis along with age at optic neuritis. Both patients had optic neuritis 
after 30 years of age and visual deficit was severe at the time. This area need 
addressing for future studies as it can improve quality of life and vision in 
Multiple sclerosis. 
 
8.8. Vision in optic neuritis group 
Vision was further studied in the positive history of optic neuritis MS group and 
the no history of optic neuritis MS group (NON MS). Data was filtered for the 2 
different groups using the split data function and thereafter group comparatives 
descriptive were used. The data was derived from the most consistent group and 
outliers were not considered. The results are presented below. 
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Table 8.11: Descriptive Statistics OPTIC NEURITIS= NO  
 
 
 N Minimum Maximum Mean Std. Deviation 
LogmarU 
65 12 60 43.31 13.135 
Sloan25U 
65 0 46 24.25 13.178 
Sloan125U 
65 0 46 15.16 12.326 
Valid N 
65     
 
Table 8.12:Descriptive Statistics OPTIC NEURITIS= YES control stats 
 N Minimum Maximum Mean Std. Deviation 
LogmarU 42 2 55 36.27 17.548 
Sloan25U 42 0 45 14.08 13.056 
Sloan125U 42 0 45 7.22 10.912 
Valid N  42     
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Table 8.13: Descriptive statistics for Severe Optic neuritis  
 
 
 
 
 
Figure 8.14: Bar chart depicting letter score on LogMAR, Sloan 2.5% and 
1.25% chart in patients with no, yes and severe optic neuritis group 
 
Total eyes  3 Minimum 
Letter 
score 
Maximum 
Letter 
score 
Mean 
Letter 
score 
Std. Deviation 
LogmarU 30 45 35.00 8.660 
Sloan25U 0 33 14.67 16.803 
Sloan125U 0 22 7.33 12.702 
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8.9. Sloan letter acuity chart in patients on DMT (disease modifying treatment)  
 
Table 8.15:Descriptive Statistics of patients on NO treatment  
 
 
Binocular N Minimu
m 
Maximu
m 
Mean Std. 
Deviation 
Skewness 
Statisti
c 
Statistic Statistic Statisti
c 
Statistic Statisti
c 
Std. 
Error 
SLOAN25 
30 0 45 28.05 13.923 -.622 .512 
SLOAN125 
30 0 45 21.10 13.034 .109 .512 
Valid N  
30       
 
 
 
 
 
 
Table 8.16: Descriptive Statistics of patients with  treatment  
Binocular  N Minimu
m 
Maximu
m 
Mean Std. 
Deviation 
Skewness 
Statisti
c 
Statistic Statistic Statisti
c 
Statistic Statisti
c 
Std. 
Error 
SLOAN25 25 0 60 24.58 16.190 .007 .421 
SLOAN125 25 0 35 14.63 13.273 .456 .427 
Valid N  25       
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Figure 8.17: Clustered bar chart depicting letter scores on Sloan 2.5% and 
Sloan 1.25% contrast chart in the treated versus untreated group.  
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8.10. Comparison of visual function tests using ROC curve analysis 
Visual function test (units) ROC curve area (95% CI)  
 
The ROC curve area represents the probability that each test will correctly 
identify the cohort participants as MS patients versus disease free controls. The 
areas range from 0.5 (no ability to distinguish Multiple sclerosis) to 1.0 (perfect 
capacity to distinguish). 
 
The vision measure with the greatest area under the ROC curve was considered 
the test that best distinguishes MS participants from controls on the basis of 
binocular visual function. Using binocular scores, low-contrast letter acuity 
(1.25% charts) had the greatest capacity to distinguish all MS patients from 
controls using logistic regression and ROC areas (ROC area 0.412, p=0.006). In 
comparison, ROC areas were decreased and did not distinguish between healthy 
controls and MS participants using binocular high-contrast acuity, 2.5% low-
contrast 
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Figure 8.18: ROC curve for different test charts check curve + CI 
 
The test result variable(s) has at least one tie between the positive actual state 
group and the negative actual state group. Sloan 1.25% chart is more specific in 
detecting the disease state compared to the other test charts. 
 
 
 
 
Table 8.19: Area Under the Curve 
Test Result Variable(s) Area 
LogMAR .190 
Sloan 2.5 .025 
Sloan1.25 .041 
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Result 2: Evaluation of colour vision in disease and control 
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Colour vision in MS 
Multiple Sclerosis (MS) frequently causes injury to the anterior visual pathway 
(AVP), impairing quality of life due to visual dysfunction. Although the 
mechanisms involved in colour vision impairment are not completely 
understood, the results of functional tests of colour vision in our study suggests 
that impaired colour vision is produced primarily by injury to the anterior visual 
pathway. 
Colour vision involves the detection of light spectra by colour-sensitive cones 
(red, green and blue light) that project to bipolar to retinal ganglion cells 
(RGCs). Axons from RGCs then project to Parvocellular and Koniocellular 
neurons in the lateral geniculate nucleus (LGN), which in turn send projections 
to the V1 region of the visual cortex.  
Hardy, Rand and Rittler (HRR) pseudoisochromatic plates allow the presence of 
acquired colour vision impairment to be evaluated at the patient’s bedside 
within a few minutes 
We sought to investigate whether assessments of colour vision augment 
measures of visual disability in MS. We studied the association between high-
contrast visual acuity charts, LCVA and colour vision using HRR (Hardy-Rand-
Rittler plates). This will later be correlated with findings of OCT, using high-
resolution spectral-domain OCT (SD-OCT, new generation). 
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The group of 55 MS patients and 25 controls underwent Ishihara and HRR 
colour testing methods. We also sub-classified the group with previous optic 
neuritis and the group receiving disease-modifying treatment in this cross 
sectional study. 
Controls: 
Twenty-five normal controls were recruited from the clinic staff and from 
relatives accompanying patients. After obtaining informed consent, 10 males 
and 15 females, aged 32to 53, were questioned for a history of colour blindness 
in themselves or in a primary relative, for a history of visual disturbance, and 
for the presence of a systemic illness that could affect vision. Following 
confirmation that there were no known visual disturbances, control subjects 
underwent the same series of tests as did the MS patients.  
 
9.2. Colour vision testing using Ishihara test charts   
 
Ishihara's Tests for colour blindness (ITCB) is a collection of pseudo-
isochromatic plates that measures colour vision and is largely independent of 
pre retinal changes .The complete edition of ITCB contains 38 plates, while a 
concise edition, assembled in 1989, consists of a subset of 14 plates. The first 
11 plates of the concise edition, identifying patients with red-green colour 
deficiency, were used in this study. Misreading up to 1 or 2 plate out of 11 was 
considered normal. 
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Table 9.1: Ishihara testing outcome 
Plate Control RE Control  
LE 
Control BE MS RE MS LE MS BE 
1 0 0 0 0 0 0 
2 0 0 0 1 0 1 
3 0 0 0 0 0 0 
4 0 0 0 2 1 1 
5 1 0 1 3 2 4 
6 0 0 0 1 0 0 
7 0 0 0 0 1 0 
8 1 1 1 2 6 2 
9 0 0 0 0 0 0 
10 0 0 0 0 0 0 
11 0 0 0 0 0 0 
12 0 0 0 0 0 0 
Total 2/25 1/25 2/25 9/55 10/55 8/55 
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9.3. HRR colour chart 
Colour vision was then tested using Hardy, Rand and Rittler (HRR) 
pseudoisochromatic plates. The HRR test has 24 plates with 0, 1 or 2 symbols 
depending of the plate. There are three types of plates: 4 non-scored 
demonstration plates; 6 scored screening plates and 14 scored plates for type 
and severity assessment. The first four plates (plates 1–4) are used to ensure 
understanding and enough visual acuity to perform the task. The 6 screening 
plates (plates 5–6 with 4 symbols for blue-yellow deficit and plates 7–10 with 6 
symbols for red-green) classify eyes as having dyschromatopsia or normal 
colour vision. An eye with less than two errors is considered normal. There is 
no need to continue the test if the HRR score is 35 (one error) or 36 (zero 
errors). We used two errors as a cut-off point to ensure a sensitivity of 1.0, as 
has been previously described. An eye with two or more errors in the screening 
plates has impaired colour vision and plates 11–24 were administered to 
determine type and extent of the defect. Plates 11–20 (18 symbols) and plates 
7–10 are used to assess red-green defect with three levels of severities: mild 
(plates 7–10 with 6 symbols and plates 11–15 with 8 symbols); moderate (plates 
16–18; 6 symbols) and severe (plates 19–20, 4 symbols). Plates 21–24 (8 
symbols) and plates 5–6 are used to evaluate blue/yellow defect  
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with three levels of severities: mild (plates 5–6); moderate (plates 21–22; 4 
symbols) and severe (plates 23–24; 4 symbols). The last group of plates in 
which errors occur establishes the extent of the color deficit. For instance, if the 
last error occurs in either plates 7–10 or 11–15 and there are no errors in plates 
16–20 there is a mild red-green deficit. In our study, color vision is evaluated 
qualitatively based on the number of errors in the screening plates: an eye has a 
color vision deficit if it has at least two errors in the screening plates. Moreover, 
color vision was measured quantitatively based on the number of correctly 
identified symbols in the 20 scored HRR plates with a maximum of 36 symbols.  
 
Statistics 
This study collects a wide range of results that was examined using the 
following standard approach. First, we performed descriptive statistics to 
characterize the sample using absolute numbers and proportions for qualitative 
variables and mean and standard deviation for quantitative variables. Data was 
tested for normality, homoscedasticity and independence to test assumptions 
used for parametric tests. Then, we performed bivariate analyses using  X
2
 test 
or Fisher test (in case of small samples) for qualitative variables and 
independent 2-sample t-test or ANOVA (three or more groups) for quantitative 
variables. For data that is not parametric, we will use the U-Mann–Whitney test. 
Pearson’s Correlation test or the non-parametric analogue, Spearman rank order 
correlation coefficient, will be used to evaluate correlations. Finally, we will 
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perform multivariate tests to rule out confusion that is inherent to cohort studies. 
Two-tailed p-values <0.05 will be considered statistically significant. All 
analyses were performed with the Statistical Package IBM-SPSS software 
version 21V 
 
9.4. Comparative data ITCB and HRR 
Table 9.2: Defective plates read in Ishihara versus HRR chart (mean) 
Defective  IHRC IHRD HRRC HRRD 
Right 2 9 2 16 
Left 1 10 3 15 
Both 2 8 5 14  
 
IHRC : Ishihara for controls, IHRD: Ishihara for disease, HRRC: HRR chart for 
control, HRRD: HRR for disease 
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Figure 9.3: Bar chart depicting the detection of colour deficit using IHR and 
HRR charts in control and disease group.  Y-axis shows the number of colour 
plates unable to read in right , left and both eyes. 
 
 
The HRR chart proved to be more sensitive to damage of the retinal ganglion 
cells, reflected by the extent of detection of colour vision deficit compared to 
the Ishihara charts. In addition, the HRR chart has the potential to classify these 
groups into mild, moderate and severe colour deficit along red –green and blue-
yellow axis. This may form an indirect clue to affection of the Magnocellular 
and Parvocellular pathway. 
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Table 9.4: HRR testing outcome: 
HRR control 
Defective colour 
vision 
IHR 
RE 
IHR 
LE 
IHR 
BE 
HRR 
RE 
HRR 
LE 
HRR 
BE 
Controls (n= 25) 6 4 5 0 0 0 
Disease (n=55) 14 10 16 16 15 14 
Mild RG - - - 10 9 10 
Mod RG - - - 4 4 2 
Severe RG/ BY - - - 2 2 2 
Normal 11 15 9 39 40 41? 
 
 
Table 9.5: Detection of severity of colour blindness 
  HRR HRR HRR 
RE LE BE 
Mild RG 10 9 10 
Mod RG 4 4 2 
Severe RG/ BY 2 2 2 
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Figure 9.6: Colour deficit in the cohort of study patient (disease arm) 
The table below shows the spread of data in the MS arm of the study. 60% of 
patients had no history of optic neuritis while 40% had history of optic neuritis 
with severe symptoms in  2.7% patients recruited. 
 
 
 
Table 9.7: showing the number of cases with no history of optic neuritis(N), 
history of optic neuritis (Y) and severe optic neuritis( Y SEV) 
 
 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
N 65 60.0 60.0 60.0 
Y 42 37.3 37.3 97.3 
Ysevere 3 2.7 2.7 100.0 
Total 110 100.0 100.0  
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This can be graphically represented by a bar chart for better understanding. 
Figure 9.7a: Bar chart depicting the visual outcome in different optic neuritis 
groups. 
 
Study group and colour blindness  
Table 9.8 shows patients with normal colour vision to range of colour deficits. 
 
Table 9.8:Extent of colour blindness 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
Mild BY 1 .9 .9 .9 
Mild RG 19 17.3 17.3 18.2 
Mod BY 2 1.8 1.8 20.0 
Mod RG 8 7.3 7.3 27.3 
Normal 76 69.1 69.1 96.4 
Severe 
RG/BY 
4 3.6 3.6 100.0 
Total 110 100.0 100.0  
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Figure 9.8a: Bar chart showing the range of colour deficits in the disease group. 
 
 
The data was then grouped into the optic neuritis group with positive history 
(yes group) and the other with no history of ON (no group). The data split 
function on SPSS Vs 21 was used and the frequencies at which patients suffered 
with colour deficit in the 2 groups were studied. 
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Interesting results were revealed as shown in the charts. 
 
A) The negative ON history group: 
66 patients had no history of optic neuritis. Hence we probably would expect 
the colour vision to be normal in this group. On the contrary, this group showed 
a variety of colour deficit which ranged from mild red green to severe red green 
deficiency and from mild blue yellow deficit to severe blue yellow deficit in 
colour vision. 
This opens a new concept of asymptomatic or sub-clinical loss of colour vision 
in Multiple sclerosis. 
Statistics 
a. No Optic neuritis  N=65 
 
Figure 9.9: Colour deficits in the disease group with no history of optic 
neuritis 
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B) The positive history of optic neuritis group 
The positive history of optic neuritis was then studied. There were 42 eyes in 
this group with 28 eyes suffering from mild to severe colour abnormalities 
termed as dyschromatopsia. We would expect a majority of the group to have 
some form of dyschromatopsia, though this was not the case. We had 14 eyes 
 ( 32%) with no detectable colour abnormalities. 
Statistics 
 
a. Optic neuritis = Yes group 
 
 
N 
Valid 42 
Missing 0 
 
 
 Total eyes 
 
Percent eyes Valid Percent Cumulative 
Percent 
Valid 
Mild RG 16 39.0 39.0 39.0 
Mod RG 8 17.1 17.1 56.1 
Normal 14 34.1 34.1 90.2 
Severe 
RG/BY 
4 9.8 9.8 100.0 
Total 42 100.0 100.0  
a. Optic neuritis = Yes group 
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Figure 9.10: Bar chart showing the frequency of normal colour vision to 
dyschromatopsia. 
 
 
C) The group with severe optic neuritis 
 
Statistics 
extent colour blind   
N 
Valid 3 
Missing 0 
a. Optic neuritis = Yes, Severe group 
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Figure 9.11: Bar chart showing severe colour deficit in positive history of optic 
neuritis group. 
 
extent colour blind 
 Frequen
cy 
Percent Valid Percent Cumulative 
Percent 
Valid 
Moderate RG 1 33.3 33.3 33.3 
Normal 2 66.7 66.7 100.0 
Total 3 100.0 100.0  
a. Optic neuritis = Y SEV 
 
 
 
 
 
 
Further the categorical data in the 2 groups was compared using a chi-squared 
test. The results are shown in Table 9.12. 
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Interpretation:  
 The results of a chi-square test, Χ2 (chi-square) value is 0.543 with 10 degrees 
of freedom for a sample size of 110. The exact significance level was 0.000, 
which meant that the 95% confidence level was merely a chance with a highly 
significant chi square value. 
 
Table 9.12:  Range of colour deficits in the 3 subgroups 
 
 
 
 
 
 
optic neuritis * extent colour blind Crosstabulation 
 extent colour blind Total 
MILD 
BY 
MILD 
RG 
MOD 
BY 
MOD 
RG 
NORMAL SEV 
RG/BY 
optic neuritis 
No 
 
 
 
 
 1 3 2 0 60 0 66 
 
100.0% 15.8% 100.0% 0.0% 78.9% 0.0% 60.0% 
 
  
       
Yes 
 
 
 
 0 16 0 7 14 4 41 
 
 
0.0% 84.2% 0.0% 87.5% 18.4% 100.0% 37.3% 
 
         
Yes 
severe 
 0 0 0 1 2 0 3 
 0.0% 0.0% 0.0% 12.5% 2.6% 0.0% 2.7% 
Total 
 
 
 
 1 19 2 8 76 4 110 
 
100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
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Table 9.13: Chi square on the 3 groups 
 
 Value df  Sig. (2-sided) 
Pearson Chi-Square 51.483
a
 10 .000 
Likelihood Ratio 57.080 10 .000 
McNemar-Bowker Test . . .
b
 
N of Valid Cases 110   
a. 14 cells (77.8%) have expected count less than 5. The minimum expected 
count is .03. 
b. Computed only for a PxP table. 
 
Table 9.14 : correlation coefficient 
 Value Approx. Sig. 
Nominal by Nominal 
Phi .684 .000 
Cramer's V .484 .000 
N of Valid Cases 110  
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9.6. Logmar , Sloan , colour chart and its correlation explored  
 
Visual function charts ( LogMAR) testing form sense  was compared with  
charts to test contrast ( Sloan 2.5 and Sloan 1.25%) and colour (HRR)chart . 
As a rule of thumb, scatter plots for each of the data set was used to explore the 
best-fit line and subsequent analysis for correlation. 
 
Figure 9.15:Scatter plot of LogMAR  and  HRR colour  chart data( both eyes) 
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Figure 9.16: Scatter plot showing Sloan 2.5 and HRR colour chart (both eyes) 
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Figure 9.17: Scatter plot showing Sloan 1.25% and HRR 
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Table 9.18: Test for bi-variate correlation (Pearson) was then done on each 
of the 2 variables as shown below. 
Correlations 
BE= both eyes Colour 
chart BE 
Sloan125
BE 
Sloan25 
BE 
Logmar 
BE 
Colour 
Chart BE 
Pearson 
Correlation 
1 .344
*
 .458
**
 .423
**
 
Sig. (2-tailed)  .010 .000 .001 
N 55 55 55 55 
Sloan125 
BE 
Pearson 
Correlation 
.344
*
 1 .801
**
 .522
**
 
Sig. (2-tailed) .010  .000 .000 
N 55 55 55 55 
Sloan25 
BE 
Pearson 
Correlation 
.458
**
 .801
**
 1 .658
**
 
Sig. (2-tailed) .000 .000  .000 
N 55 55 55 55 
Logmar 
BE 
Pearson 
Correlation 
.423
**
 .522
**
 .658
**
 1 
Sig. (2-tailed) .001 .000 .000  
N 55 55 55 55 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
 
The above table and scatter plot indicates a positive correlation between colour 
vision, LogMAR and Sloan charts.  
The scatter plot though shows a positive correlation exhibiting strong proximity 
to the best-fit lines. There are few outliers, which generate negligible error in 
the interpretations.  
 
The Pearson correlation and its significance in the above table help us make 
some conclusive assumptions. The correlation coefficient of each pair is very 
significant. Sloan 1.25% chart shows a significance of 1, which indicates a 
strong correlation between disturbance in colour vision and disturbance of 
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contrasts vision in disease-eyes due to damage of retinal ganglion cells 
(RGC) in MS. Color vision, reflects damage of retinal ganglion cells (RGC) and 
hence can serve as a marker of RGC 
damage in MS. 
 
Figure 9.19: Age at optic neuritis and deficiency of colour vision 
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Table 9.20 : Correlations (significant at the 0.01 level ( 2 tailed) 
 Colour read age@on 
Colour read 
Pearson Correlation 1 -.562
**
 
Sig. (2-tailed)  .000 
N 44 44 
Age@ on 
Pearson Correlation -.562
**
 1 
Sig. (2-tailed) .000  
N 44 44 
 
 
9.7. Age at optic neuritis  
 
The result of the number of colour chart read by patients in the optic neuritis 
group was explored. The data was split using the data function on SPSS. 
Further a scatter plot was applied to this subgroup. 
Interesting results revealed a significant negative correlation between the ability 
to read the test plates on the colour chart and age at optic neuritis. 
Patients with early onset optic neuritis (age of 25 or less) had better colour 
vision compared to the late onset optic neuritis (>than 25years of age). This 
throws light on the mechanism of repair and macrophagic activity in early onset 
optic neuritis in MS.  
This fact can be tested further by future researchers by conducted studies on a 
bigger sample. 
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                                           Result 3: 
 
 
Evaluation of Humphrey’s visual fields in disease and control 
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10.1. Humphrey’s Visual field test 
The Humphrey Visual Field is standard tests that allow us to look for defects in 
the sensitivity of the eye. 
All patients and controls had Humphrey test performed. There were few 
occasions that the patients were fatigued and hence patients had to be retested to 
obtain a reliable field. Unreliable fields were discarded as no conclusion can be 
drawn from those fields. We did   the 24-2, SITA Standard (Swedish Interactive 
Threshold Algorithm) testing protocol.  
All patients were tested using the current prescription glasses. A automated 
focimetry was performed to calculate the refractive error which could then be 
incorporated into the testing system. 
Patients had a good explanation about the procedure and few patients had 
undergone similar testing at the opticians in the community. There was no 
difficulty in obtaining reliable fields in all patients and controls though we had 
to repeat tests in 8patients to obtain consistent results. Out of the 8, 5 had a 
second testing and 3 had three testing done before obtaining acceptable fields. 
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The parameters that were considered in the visual field tests are mentioned 
below: 
1) Mean deviation 
2) PSD 
3) 8X8 square along the central fixation was analysed and correlated with 
posterior pole OCT. 
Table 10.1: Mean deviation in controls and cases 
Mean deviation 
in decibels 
Controls Disease Optic 
neuritis 
group 
Negative 
optic 
neuritis 
group 
Mean -2.13019 -6.74 -6.2 -5.9 
Median -1.98 -6.3 -6.1 -5.3 
Standard 
deviation 
0.728 3.025 2.01 3.2 
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Figure 10.2: Bar chart representing the data on mean deviation in control 
and cases
 
Pattern Standard deviation (PSD) 
The study of PSD showed significant results. Though the loss of function was 
global there was a pattern to superior, inferior, nasal or temporal visual loss. 
Table 10.3: Pattern standard deviation in controls and disease 
PSD in dB Controls Disease Optic 
neuritis 
group 
Negative Optic 
neuritis group  
Mean -1.13 -5.74 -5.94 -3.2 
Median -1.36 -5.3 -5.5 -2.9 
Standard 
deviation 
0.92 2.92 1.1 0.6 
-6
-5
-4
-3
-2
-1
0
1
2
3
4
mean median Sd control
disease
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8X8 square of  Visual sensitivity   
This specific parameter was tested and its correlation with RNFL thickness on 
posterior pole OCT analysis was explored. This correlation will be presented in 
the posterior pole OCT chapter. 
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Result 4: Evaluation of parameters on OCT in disease and 
controls. 
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11.1. Optical Coherence Tomography in Multiple Sclerosis:  
 
A structural assessment: A window into the mechanisms of Multiple Sclerosis 
 
The pathophysiology of multiple sclerosis (MS) is characterized by 
demyelination, which culminates in a reduction in axonal transmission. Axonal 
and neuronal degeneration seem to be concomitant features of MS and are 
probably the pathological processes responsible for permanent disability in this 
disease. The retina is unique within the CNS in that it contains axons and glia 
but no myelin, and it is, therefore, an ideal structure within which to visualize 
the processes of neurodegeneration. 
Optical coherence tomography (OCT) can provide high-resolution 
reconstructions of retinal anatomy in a rapid and reproducible fashion ideal for 
precisely modelling the disease process in MS. 
Aim: To determine the relation between parameters on OCT and visual function 
tests. 
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11.2. Methodology 
Structural assessment was done using with the Spectralis OCT and analysis was 
run on RNFL, GCIP, Macular volume, PPRNFL, Choroid and RNFL of 
posterior pole. 
The structure was correlated with function of vision such as form, contrast, 
colour and  visual field using  LogMAR, Sloan , HRR charts along with 
parameters on visual fields. 
11.3.Testing for coefficient of repeatability (variability) 
We estimated coefficients of repeatability for Spectralis optical coherence 
tomography (OCT)-derived automated retinal thickness and volume 
measurements in 10 healthy patients and 10 patients with Multiple Sclerosis, not 
recruited into the study, though fulfilling the inclusion and exclusion criteria for 
the study.  
The patients underwent four consecutive "fast" volume scans at a single session 
using one OCT device operated by one of two experienced operators. Bland-
Altman coefficients of repeatability (CR) were calculated for automated retinal 
thickness measurements, center point thickness, total macular volume, RNFL, 
GCIP and PPRNFL. Scans were evaluated for significant automated retinal 
boundary detection error and revised estimates for CR calculated with these 
scans excluded. 
192 
 
Coefficient of reliability in controls and disease 
CR for the macular volume was 1.03μm (95% confidence interval [CI] 0.89 -
1.35μm). The CR for RNFL and GCIP ranged from 2.54 to 3.25μm.  The CR 
for PPRNFL was 4-6μm. Scan sets of subjects did not show any significant 
boundary detection error and centre recognition error. 
 
Retinal thickness measurements in subjects with MS obtained using Spectralis 
OCT are considerably less variable and consistent with good coefficient of 
reliability and repeatability. 
We used the Spectralis OCT, Heidelberg, Germany. The benefits of high 
resolution, eye tracking, reference setting, noise reduction and low coefficient 
of variability were the benefits of using the Spectralis model with auto 
segmentation technology. We had financial constraints to obtain the N-Site 
software to analyse the PPRNFL and hence we continued assessments using the 
existing software.    
(The N-site Analytics
™
 software provides a unique analysis of the peripapillary 
RNFL. Based on the N-site normative database, a classification colour scheme 
indicates not only axonal loss but also oedematous changes). 
Macular OCT allows us to image the retinal nerve fiber layer (RNFL) at the 
macula .In contrast ,the ONH OCT images  the peripapillary RNFL, which 
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contains axons, the macula contains a large proportion of retinal ganglion cell 
neurons (about 34% of total macular volume). Hence study of different structure 
gives an overarching idea of the disease process in demyelinating optic 
neuropathy. 
 
11.4. The parameters in the study are discussed in great details below. 
1. Macular OCT RNFL 
a) GCIP 
b) Macular volume 
2. Optic nerve OCT 
c)  PPRNFL 
 3. EDI OCT 
d)  Choroid  
4. Posterior pole OCT 
      e) Asymmetry analysis 
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      Figure 11.1: OCT of Optic nerve head (ONH)  
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Top image: The green line indicates the location of where the OCT image is 
taken around the Optic Nerve Head (ONH) 
  
Second Image: The OCT scan is automatically segmented between the two red 
lines (the internal limiting membrane to the Retinal Nerve Fiber Layer (RNFL)) 
  
Third Image: The black line indicates the RNFL thickness for this 
patient.  Colour coding is as indicated between the two graphs. 
  
Bottom: Pie charts indicate sector thickness in the nasal, temporal, superior and 
inferior areas around the ONH, indicating borderline thinning in the temporal 
segment in the left eye. 
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Figure 11.2: Normal OCT scan of macula 
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Figure 11.3: Posterior pole OCT   showing the 64 grid macular   and 
asymmetry analysis. 
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Figure 11.4: Single Exam report of Macular thickness map 
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11.5. OCT parameters in cases and controls 
We studied the cases and controls for OCT parameters such as: 
1) Retinal nerve fibre layer thickness (RNFL) 
2) Ganglion cell –inner plexiform complex (GCIP) 
3) Macular volume (MV) 
4) Peripapillary RNFL (PPRNFL) 
5) Posterior pole OCT (PPOCT) 
6) Enhanced depth imaging OCT (EDI-OCT)  
Table 11.5: Macular OCT parameters in Cases 
N=110 Macular 
Volume 
mm cube 
Macular 
RNFL 
Thickness 
microns 
Ganglion cell- 
Inner plexiform 
Thickness 
microns 
Peripapillary 
RNFL 
microns 
Mean 7.935 23.99 82.43 85.91 
Median 7.9 25.185 83.5 86 
Standard 
Deviation 
0.8351 5.26 8.86 15.49 
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Figure 11.6:Bar chart showing the  OCT parameters in Cases. 
The disease group had a mean macular volume of 7.935 (cubic mm) with a 
standard deviation of 0.835.  
The mean macular RNFL was 23.99 microns with a standard deviation of 5.26 
microns. 
The mean GCIP was 82.43 microns with a standard deviation of 8.86 microns. 
The PPRNFL was 85.91 microns with a standard deviation of 15.49 micron. 
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 Table 11.7: OCT parameters in Controls 
N=50 Macular 
Volume 
mm cube 
Macular 
RNFL 
Thickness 
microns 
Ganglion cell- 
Inner 
plexiform 
Thickness 
microns 
Peripapillary 
RNFL 
Microns 
Mean 9.2 29.6 88.9 92.76 
Median 8.91 29 88.6 91.76 
Standard 
Deviation 
1.76 6.12 8.87 10.24 
 
 
Figure 11.8: Bar chart showing the  OCT parameters in Controls. 
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The control group had a mean macular volume of 9.2 (cubic mm) with a 
standard deviation of 1.7.  
The mean macular RNFL was 29.6 microns with a standard deviation of 6.12 
microns. 
The mean GCIP was 88.9 microns with a standard deviation of 8.87 microns. 
The PPRNFL was 92.76 microns with a standard deviation of 10.24 microns. 
Table 11.9: Comparative data control versus cases 
 Control Disease 
Mean macular volume 
(cubic mm) 
9.2 7.9 
Mean Macular RNFL 
(microns) 
29.6 23.99 
Mean GCIP (microns) 88.9 82.43 
Mean PPRNFL (microns)  92.76 85.91 
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Figure 11.10 :Bar chart showing the comparision of   OCT parameters in 
Controls versus cases. 
The cases were further split into the ones who had optic neuritis. Analysis was 
redone in the subgroup. (Table 11.1) 
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Table 11.1  Controls 
N= 
All Cases 
N=  
Cases with history 
of optic neuritis 
N= 
Cases with no 
history of optic 
neuritis 
Mean macular 
volume 
9.2 7.9 6.43 8.1 
Mean macular 
RNFL 
29.6 23.99 21.65 24.98 
Mean GCIP 88.9 82.43 79.34 84.00 
Mean PPRNFL 92.76 85.91 79.75 86.91 
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Table 11.1 and figure 11.2 : Comparative data of control , cases and those with 
optic neuritis 
11.6. Conclusion 
The thickness of the macular RNFL was reduced by 27% in the affected eyes of 
the patients with MS versus the control eyes (P<0.01), and by 8% when affected 
eyes were compared with the ‘unaffected’ eyes of the same patient (P<0.01). 
Even in the clinically unaffected eyes of patients, however, there was a 13% 
reduction in RNFL thickness when compared with control eyes (P<0.01). 
 The macular volume (a reflection of retinal ganglion cell neuronal integrity) 
was reduced by 31% in the eyes of patients with a history of ON when 
compared with control eyes (P<0.001), and by 17% in the affected versus the 
unaffected eye of the same patient (P<0.001). 
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 Patients with MS who have ON sustain 10–40 µm of RNFL loss within a 
period of approximately 3–6 months. This finding is striking given that the 
RNFL is only about 110–120 µm thick by the age of 15 years, and that most 
normal will lose only about 0.017% per year in retinal thickness, which equates 
to a decrease of approximately 10–20 µm over 60 years. 
 The patients have to be followed for few years to identifying an injury 
threshold within the RNFL and thinning of the RNFL that corresponds to 
decline in visual function, as measured by contrast charts and automated 
perimetry. 
This does call for a prospective study in future for a minimum duration of 5 
years to be conducted in such patients to determine the threshold of the RNFL 
injury at which visual loss becomes evident. This will generate a patient specific 
RNFL threshold instead of a blanket approach to RNFL loss in MS. 
Macular volume and macular RNFL show a strong correlation in disease. A 
drop in 14% of the macular volume in cases correlated with a drop in macular 
RNFL by 19% .The eyes with Optic neuritis showed more profound correlation 
with a drop in macular volume by 31% and 27% drop in macular RNFL. 
Macular RNFL seems to be a sensitive parameter determining change in 
threshold vision. GCIP is more sensitive to changes in patients with positive 
history of ON.  
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Table 11.3: Comparative data of OCT parameters in cases, controls, optic 
neuritis and treatment group 
 
 
 
 
 
Thickness in 
millimeters 
Cases  
(p values)  
Controls Optic neuritis 
group 
Treatment group 
Macular volume  7.9 
(0.001) 
9.2 6.43 8.1 
Macular RNFL 23.99 
(0.01) 
29.6 21.65 25.3 
GCIP 82.43 
(0.0001) 
88.9 79.34 85.2 
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           Result 5: Enhanced depth imaging (EDI-OCT) for the choroid 
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Enhanced Depth Imaging  OCT ( EDI) 
EDI-OCT is a new imaging modality to enable high-resolution OCT imaging of 
the choroid along with retinal layers and lamina cribrosa. It allows detecting 
structural changes ‘beyond the retinal pigment epithelium’ in a reproducible 
fashion difficult to capture with standard OCT. This function is unique to the 
Spectralis model of OCT that we used in our study. During a single 
examination, it can be easily switched between ‘normal’ and ‘EDI-OCT’ mode 
making it friendly for both the patient and the operator. 
Figure 12.1: Image below showing the EDI function in use on the Spectralis 
model of OCT. Note the difference from the upper image with no clear 
definition of choroid and sclera . 
 
 
 
 
210 
 
12.1. Aim and methodology 
All patients and controls underwent EDI OCT. A total of 110 scans were 
obtained from the disease and 50 scans obtained from the controls. 
The main aim for using the EDI OCT: 
1) To explore the thickness of the choroid in patients with Multiple 
Sclerosis, compare it to the controls. Multiple sclerosis is an autoimmune 
condition which results from a breakdown of the blood brain and blood 
ocular barrier. The Retinal pigment epithelium (RPE) forms the outer 
ocular barrier and separates the retina from the vascular choroid. There 
are no studies until date that has looked at the choroid in MS and control. 
 
2) Embryologically the choroid layer along with ciliary body is similar to 
the choroidal plexus in the brain. Choroid plexus secrete the 
cerebrospinal fluid and oligoclonal bands have been detected in patients 
with MS in the CSF. Choroid is the main vascular bed and Bruch’s 
membrane contributes to the retinal barrier. Though it is challenging to 
study the composition of the blood in the choroid, it is not impossible to 
study its structure. The structure of choroid may give an indirect clue to 
the function of the vascular system. The recent introduction of EDI OCT 
has made it possible to study the structure of the choroid in great detail. 
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12.2. Results  
We studied the thickness of the choroid in both cases and controls. The spread 
of data is represented in the table (12.2) below. 
EDI Mean  
microns 
Median 
microns 
SD 
microns 
First 
quartile  
Third 
quartile  
Controls 261 267 13 265 287 
Cases  263 267 71 236 289 
Table 12.2: EDI OCT in controls and disease 
 
 
 
Figure 12.3: EDI OCT in controls and disease  
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The cases were further studied in the range of thickness they exhibited to see if 
the groups were any different. 
 
Table 12.4:  Grouping of cases based on choroid thickness 
 
EDI (thickness) 200-316 >316 <200 
Cases  85 12 13 
Thickness Normal  Thick Thin 
 
The EDI was studied in the 3 sub-groups and a sub group analysis was done. 
1) EDI (200-316 microns) 
Patients with multiple sclerosis seem to have a greater SD of 71 compared to 
that of 13 in the control group. The group had variable ocular parameters and a 
correlation was established with the LogMAR, Sloan Chart and color charts. 
Correlation was also carried out on the retinal parameters using OCT such as 
mean RNFL and GCIP. 
2) EDI (> 316microns) Mean 332 and Standard deviation 18 
Patients in this group either had history of optic neuritis, poor letter scores on 
Sloan2.5%, Sloan 1.25% charts and color charts with progression of EDSS with 
time and were treated with disease modifying agents. Overall, this group 
represented the active MS group. 
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3) EDI (< 200 microns) Mean 157 and SD 17 
 
Patients in this group had a history of severe optic neuritis with reduced visual 
function after the episode. Patients were treated with 3-5 course of intravenous  
steroid during the span of the disease process. They had poor letter scores on 
Sloan’s chart especially 1.25% and had variable relation to EDSS. 
12.3. Conclusion:  
EDI- OCT forms an important investigative modality in the autoimmune related 
neuro-degenerative process in Multiple Sclerosis. The process of 
neurodegeneration is reflected by the thinning of the retinal nerve fiber layer in 
chronic cases while the autoimmune activity is reflected by the thickness of the 
choroid. 
Thicker choroid in Multiple sclerosis may indicate an active immune process 
and can form an important adjunct to neurological assessment, such as EDSS 
and MSFC. EDI OCT can most probably be used to detect response to disease 
modifying treatment and can form a prognostic indicator. This study has to be 
extended to a bigger cohort of patients to confirm the findings of this 
preliminary study. 
Thinner choroid indicates a moderate to severe global neurodegenerative 
process as shown by suppressed ocular and neurological function. Steroids are 
commonly used immunosuppresant during a period of relapse. The use of 
steroid during a relapse is debatable, as it is known to accelerate the neuro-
degenerative process of global neurons on a long-term follow up. There are no 
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guidelines on patient selection for use of steroids, neither is there a way of 
monitoring response to treatment after a steroid pulse treatment. 
As ophthalmologist, we use the term steroid responders in those who intraocular 
pressure raises after treatment with topical steroids.  EDI-OCT may help in 
identifying patients and sub-grouping them into steroid responders and non-
steroid responders. It may help in patient selection and setting up a guideline for 
use of steroid in this complex disease. 
In short, it will help identify patients who will overweigh the benefits in contrast 
to risk of treatment with steroid therapy. 
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              Results 6: Posterior pole OCT in cases and controls 
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Posterior pole OCT 
The Posterior pole OCT is one of the common OCT protocol used in 
Ophthalmology for patient with suspicion of glaucomatous neuropathy. It 
mainly analyses the RNFL at the optic disc and peri-papillary zone along with 
assessment of the RNFL in the 8X8 mm zone centered on the fovea, aligned on 
the disc. 
13.1. Aim of the study 
1) To provide a quantitative comparison of the retinal thickness in the 
macula and circum -papillary retinal nerve fiber layer (RNFL) defects, in 
Multiple sclerosis and controls. 
2) To explore and detect if posterior pole asymmetry can be characterized to 
optic neuropathy in MS 
3) To correlate macular thickness on posterior pole OCT with Humphrey 
visual field (HVF) parameters 
13.2. Patients and methods: 
The patients and controls in the study underwent bilateral SD-OCT (Spectralis, 
Heidelberg Engineering,) using the GDA (glaucoma diagnostic) scan protocol. 
The protocol includes measurement of the RNFL in the optic nerve, 
circumferential peri-papillary area and posterior pole macular thickness analysis 
protocol. Briefly, the macular thickness analysis measures retinal thickness 
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along 64 squares in the central 20 degrees of each eye. The area is divided into 
an 8×8 mm grid, centered on the foveal pit and aligned with the optic disc, and 
consisting of small 3 degree by 3 degree squares, with the mean retinal 
thickness of each small square displayed. In addition, the average total retinal 
thickness, as well as the average retinal thickness for each macular superior-half 
and inferior-half, are calculated and displayed for each eye. The RNFL 
measurement is displayed as an average thickness for the quadrants as well as 
with the superior and inferior quadrants divided into nasal and temporal sections 
each.  
Figure 13.1, shows an example of posterior pole OCT data collected from one 
of the study MS patient.  
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Figure 13.2, Spectral domain optical coherence tomography (SD-OCT) with 
asymmetry analysis.  
 
A. Visual field and SD-OCT analysis of the retinal nerve fiber layer (RNFL). 
The pattern standard deviation plots show a dense superior altitudinal defect and 
an inferior nasal defect in the right eye, with corresponding RNFL thinning 
inferiorly more than superiorly. In the left eye, the visual field shows some non-
specific central and nasal areas of decreased sensitivity. The RNFL average 
thickness by quadrant is normal; however, the RNFL tracing shows a dip infero-
temporally. 
 B. Asymmetry analysis of the posterior pole. The retinal thickness map 
overlays the infrared photo of the posterior pole for each eye. Inferior thinning 
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is noted in both eyes, seen quite clearly in the colour map; in addition, the 
RNFL defect noted in the left eye in (A) is seen to extend well into the macula. 
Figure 13.3 showing point to point nalysis on posterior pole oct 
 
The asymmetry analyses are displayed as gray-scale maps, with respective 
thinning shown progressively darker (30μm difference appears black, 20μm 
difference gray, and no difference or thickening appearing white). The 
asymmetry analysis comparing the right and left eyes (located between the 
maps) shows significant global thinning of the right eye compared with the left. 
The asymmetry analysis comparing the superior and inferior hemifield as well 
as the average retinal thickness measurements (total, as well as superior and 
inferior averages) are shown below the maps.  
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13.3. Results: 
55 MS patients and 25 controls had OCT testing for Posterior pole analysis. All 
patients had visual field test carried out by Humphrey’s field analyser.     
Retinal thickness in the macula and peri -papillary area, in Multiple sclerosis 
and controls. 
The peripapillary RNFL was analysed in disease and controls. The disease 
group showed an 8% decrease in the nerve fibre layer thickness compared to the 
control group and a 15% decrease in the peripapillary RNFL in the optic 
neuritis group. There was a 7% difference in RNFL between the optic neuritis 
group versus the no optic neuritis group. There was marked dip in the temporal 
RNFL of the optic disc in cases with and without optic neuritis. The loss of 
temporal fibers accounted for 25% drop in RNFL when compared to controls 
and 32% drop in RNFL in optic neuritis group. 
Table 13.4:   PPRNFL in control, disease and optic neuritis group 
Mean 
thickness 
controls disease Optic neuritis group 
PPRNFL 92.76 85.91 79.75 
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Figure 13.5: Graph showing PPRNFL in control, disease and optic neuritis 
group. 
Table 13.6:  Comparison of superior , inferior , temporal and nasal fibres. 
PPRNFL Controls Disease Optic neuritis 
group 
DMT group 
Temporal 54 49 33 47 
Nasal 63 59 49 63 
Inferior 102 78 69 72 
Superior 98.8 83 77.8 82 
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Correlation of total macular thickness on posterior pole OCT with global 
measure of visual field were analysed.  
 
 
Posterior pole OCT parameters were correlated with Visual field indices. Every 
square in the posterior pole OCT subtends an angle of 3 degrees, making it a 12-
degree testing on assessment when considered from the fovea. A, 10-2 visual 
fields subtends a 10 degree angle and hence measures visual field indices in the 
10 degrees. The average total macular thickness (in the 8×8 mm grid) of all 
subjects was 289(Table 13.7). 
 
 Eyes with thinner average total macular thickness (<270μm) had more negative 
MD scores (MD −7.76) and higher PSD scores (PSD 6.83), corresponding to 
significant visual field deficits. In eyes with average macular thickness >300μm, 
the visual field parameters were virtually normal (MD 0.89 and PSD 1.81). In 
eyes with intermediate thickness (between 270 and 300μm), the visual field 
parameters were also intermediate (MD −2.27 and PSD 3.39). 
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Table13.7: MD, mean deviation score on the Humphrey visual field; PSD, 
pattern standard deviation on the Humphrey visual field 
N 
Define groups 
Average 
macular 
thickness 
Mean MD Mean PSD 
Thin group  <270 μm −7.76 (SD 
7.78) 
6.83 (SD 3.04) 
Intermediate 
group  
270–300μm −2.27 (SD 
2.17) 
3.39 (SD 1.32) 
Thicker group  >300 μm 
0.89 (SD 1.15) 1.81 (SD 0.83) 
 
Statistical analysis was done on this data using a bivariate fit analysis. 
 Figure 13.8.Macular thickness correlates with mean deviation (MD) and 
pattern standard deviation (PSD) scores. A. Bivariate fit analysis of average 
total retinal thickness of the macula compared with the MD score of the 
Humphrey visual field for each study subject, shown by graphical plot. B. 
Bivariate fit analysis as in (A), showing the comparison of the macular 
thickness to the PSD score of the Humphrey visual field. 
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Bivariate fit analysis (Fig 13.8) shows a significant correlation between average 
macular thickness and both the MD score (Fig. 13.8A) and PSD score (Fig. 
13.8B). Regarding the correlation between MD and macular thickness, the 
correlation coefficient is 0.431, R
2
 0.185, linear fit (average macular 
thickness=287+1.55MD), with P = 0.0001. The correlation between PSD and 
macular thickness showed a correlation coefficient of −0.508, R2 0.258, linear 
fit (average macular thickness=294–3.61PSD), with P< 0.0001.  
 
Correlation of the asymmetry between the right and left visual fields with 
the asymmetry in total macular thickness between the eyes 
Asymmetry in visual fields has not been explored in Multiple sclerosis until 
date. The difference in the average total macular thickness between the 2 eyes 
was calculated and compared with the difference of the global parameters of the 
HVF between the 2 eyes. The results show that patients with greater visual field 
defects in the right eye were found to have thinner macular thickness in that 
eye, and similarly, greater visual field defects in the left eye was associated with 
thinner macular thickness in the left (table 3). An absolute difference in MD 
score of 3 correlated with a difference in average macular thickness of 
approximately 11 to 13μm between the eyes. 
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Table 13.9: Subgroup analysis of posterior pole OCT 
 
 
 
Sub group 
analysis 
Mean 
difference in 
MD score 
between eyes 
Mean 
difference in 
average 
macular 
thickness 
(micron) 
Mean macular 
thickness 
(micron)  
Right eye OD 
Mean macular 
thickness 
(micron) 
Left eye OS 
OD worse 
than OS (>3) 
N=24 
9.28 (SD 
8.97) 
14 (SD 7) 266 (SD14) 276 (SD14) 
OD similar to 
OS  N=65 
0.22(SD 1.26) 1(SD 7) 286 (SD15) 287(SD 16) 
OS worse 
than OD( >3) 
N= 22 
8.21(SD 4.33) 12(SD 12) 284 (SD16) 273 (SD23) 
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Correlation of the Asymmetry in the Macular Thickness of the Inferior 
Macula and Superior Macula with PSD Score 
Asymmetry within each eye was observed by noting the difference in the 
average thickness of the superior macula and inferior macula (Fig. 3). The 
difference in macular thickness between the superior macula and inferior 
macula was compared with the PSD score of the visual fields. Greater 
asymmetry, or difference in thickness between the superior and inferior 
maculae, correlated strongly with a larger PSD score, both in the event of worse 
superior thinning and worse inferior thinning. For eyes with superior thinning, 
the correlation coefficient is 0.575, R
2
 0.331, linear fit (difference in macular 
thickness=2.03+1.65PSD), with P< 0.0001 (Fig. 3), and for eyes with worse 
inferior thinning, the correlation coefficient is −0.697, R2 0.367, linear fit 
(difference in macular thickness = −1.54–1.20PSD), with P = 0.0022. 
Figure 13.10: Correlation fit between macular thickness and PSD 
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Asymmetry in macular thickness correlates with pattern standard deviation 
(PSD) scores. Bivariate fit analysis of the difference in average macular 
thickness (superior-half minus inferior-half) compared with PSD of the 
Humphrey visual field for each study subject, shown by graphical plot. This plot 
represents the data from subjects with superior macular thinning; results from 
subjects with inferior macular thinning are similar. 
Correlation of the Asymmetry in Macular Thickness with Asymmetry in 
the RNFL 
Given the current understanding of the pathophysiology of demyelinating optic 
neuropathy, correlation between RNFL defects and macular thickness is not yet 
fully known(Fig. 13.11, Table 13.11a). Subjects with a supero-temporal defect 
in the RNFL were more likely to have superior thinning of the macula (on 
asymmetry analysis comparing retinal thickness of the superior macula and 
inferior macula); the correlation coefficient is 0.746, R
2
 0.557, linear fit 
(difference in sup-temp RNFL = 4.33 + 2.20×difference in macular thickness) 
with P< 0.0001 (Fig. 13.11a). Similarly, subjects with an infero-temporal RNFL 
defect were more likely to have inferior thinning of the macula on asymmetry 
analysis, with a correlation coefficient of 0.845, R
2
 0.715, linear fit (difference 
in inf-temp RNFL = 4.21 + 2.36×difference in macular thickness), P< 0.0001 
(Fig. 13.11b). 
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Figure 13.11 A and B 
Retinal nerve fiber layer (RNFL) asymmetry correlates with asymmetry of 
macular thickness. A, Bivariate fit analysis of the difference in supero-temporal 
RNFL thickness between the right and left eyes compared with the difference in 
macular thickness of the superior-half between the 2 eyes, shown by graphical 
plot. B, Bivariate fit analysis as in (A), shows the comparison of the infero-
temporal RNFL thickness with the thickness of the inferior-half of the macula. 
13.4. Discussion 
This study helps to further clarify the structure-function relationship between 
retinal thickness and visual field testing results. In this study, we have been able 
to demonstrate how the analysis, which is useful in identifying and quantifying 
areas of  RNFL damage, correlates with visual function, specifically to HVF 
parameters. 
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Our data show that eyes with a total macular thickness of <270μm were 
significantly more likely to be associated with visual field loss, by both MD and 
PSD. However, eyes with a total macular thickness of >300μm were less likely 
to be associated with visual field losses. Asymmetry of the macular thickness, 
either when comparing the 2 eyes to each other or the superior macula to the 
inferior macula within the same eye, was significantly associated with a worse 
visual field localizing to the thinner retina or thinner retinal half, respectively. 
Finally, we were able to demonstrate the strong correlation between RNFL and 
macular thickness measurements. 
Measurement of both the RNFL and the macular thickness provides additional 
useful information in the diagnosis and management of Multiple sclerosis 
patients. Further delineation of the structure-function relationship between 
retinal thickness and visual field testing could allow for a more objective 
diagnosis of MS by documenting loss of retinal tissue at the posterior pole, 
particularly in patients in an early stage of the disease or where a reliable visual 
field cannot be obtained. In addition, in cases where the diagnosis of MS is not 
yet made, a quantitative analysis of macular and RNFL thickness may provide 
key information that aids in the determination of the appropriate level of therapy 
required. The high intervisit reproducibility of the SD-OCT is useful in 
detecting small but significant changes during the course of observation or 
treatment. When interpreted in the context of an individual patient, the 
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additional information provided by the SD-OCT may alter clinical decision 
making in cases where the diagnosis or the extent of damage is not 
straightforward by other clinical parameters. This information can also be 
critical in guiding therapeutic decisions in patients who cannot do a reliable 
visual field examination. 
In our study, the structure-function correlations between visual field parameters 
and macular thickness show how macular thickness as measured by SD-OCT 
can help in confirming the existence and extent of visual field defects. In this 
study, axial scans covering a 8 mm diameter area of the macula were acquired 
and the macula was divided into  sectoral zones with a total of 64 zones 
protocol. We found a correlation between both the average macular volume and 
the average RNFL thickness with visual field MD. The data suggest that OCT 
of the macular is more reproducible than of the RNFL. Building upon these 
findings, our study shows a relationship between macular thickness, as 
measured by high resolution SD-OCT of a large area of macula (8 × 8 mm 
grid), and the MD and PSD of the HVF, well-established parameters for 
monitoring  progression over time, offering a possible translation of structure 
into function. The ability to translate the structure of the macula into an 
understanding of its function is possible with SD-OCT. A method to compare 
structural and functional measures of damage using probability maps is another 
exciting advancement using OCT and visual field data.  
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As the ability to reliably measure these layers in patients improves, this will 
undoubtedly be the next step in refining our ability to correlate structure with 
function. 
Asymmetry is important and has been established by this study in the diagnosis 
of Multiple sclerosis. Our protocol includes an 8 × 8 mm area of the macula. 
We have been able to show how within a single eye, asymmetry of retinal 
thickness (either thinner superior macula or inferior macula) correlates 
significantly with higher PSD. Asymmetry between the eyes also corresponds to 
visual field defects, with the eye with the thinner macula correlating to the 
higher MD. Demonstration of asymmetry in an objective test such as the OCT 
may help the patient's understanding of the severity of disease, perhaps 
ultimately improving the approach to treatment by clinicians. 
Finally, the analysis of the visual fields relied on parameters of MD and PSD, 
which are global measures. The PSD has a parabolic distribution and given the 
large spectrum of the disease represented in this group, our correlation analyses 
may underestimate the association between this visual field parameter and the 
retinal thickness. An analysis using individual numerical data points of the HVF 
provides stronger structure-function correlation of macular thickness to visual 
field deficit.   
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In conclusion, our results show a significant point-to-point correlation between 
the visual field sensitivity and RNFL. Further study using the Short wavelength 
automated perimetry will help in further precision in certain subtypes and 
determining response to disease modifying treatment.  
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                 Final Results: Structure meets Function 
 
                          “Eye is a window to the brain” 
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Vision in Multiple Sclerosis (MS):  
 14.1. Structure-Function Correlations 
Visual dysfunction is one of the most common clinical manifestations of 
multiple sclerosis (MS). We assessed structure and function of visual system 
and correlated it with function of the neurological system 
 Function of visual system was assessed using: 
1) The LogMAR chart 
2) Sloan 2.5% and Sloan 1.25% chart   
3) The HRR color vision chart and  
4) Humphrey’s visual field analyser.  
The structure of the Visual system was assessed using: 
1) The ocular coherence tomogram of the macula, to assess the RNFL in the 
macula, macular volume and thickness of various layers of retina using 
the auto-segmentation function on OCT. 
2) The EDI protocol of OCT was used to determine the choroid thickness in 
each eye. 
3) The OCT, Optic nerve head protocol was used to scan the optic nerve and 
peri-papillary area for RNFL assessment. 
4) Posterior pole OCT. 
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The neurological function was assessed using: 
1) EDDS 
2) QOL short questionnaire 
14.2 Statistical Methods: 
The individual chapters explored the findings in case and control in a structured 
fashion, exploring and presenting on; 
1) Descriptive statistics  
2) Checking the spread of data and its normality 
3) Applying bivariate analysis for qualitative data 
4) Describing the ROC curve when appropriate 
5) Applying correlation to the group either Pearson or spearman as 
appropriate.  
In this final chapter, we try to explore the effect of multiple factors relating to 
structure and function of visual pathway and neurological function. SPSS has 
been used and a multivariate regression model with 2 tailed significance of p 
less than 0.05, taking into consideration the adjusted p values on Bonferroni’s 
correction. 
Odds ratio has been depicted to determine the predictive value of each of the 
test in segregating the control population from the diseased. 
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We have applied the broken stick model for relation between the RNFL and VF 
test, as this has not yet been explored in MS. The tipping points have been 
determined and scatter plots have been used to explore the points at which the 
loss of retinal nerve fiber layer becomes significant as evident by worsening of 
function. 
 
One eye or two eye model 
Studies pertaining to eyes usual generate 2-fold data in most cases due to the 
binocular nature. There has always been debate surrounding one eye data or two 
eyes. We have considered one eye or two eye model based on the outcome 
being correlated. For example, binocular data has been considered for 
comparison with EDSS and quality of life, while uniocular data has been used 
for most visual parameters. The overall effect of vision has then been explored 
by binocular data. Inter eye correlations has been used when appropriate. 
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14.3. Results: 
Composite study of structure with function 
Multiple sclerosis is a complex disease with many unanswered questions in 
relation to diagnosis, prognosis and response to treatment. Studies in MS have 
tried to answer the questions by studying genetics, environmental factors, 
neurological parameters such as EDSS, MSFC and cognitive testing, 
psychophysical tests and recent numerous studies on Magnetic Resonance 
Imaging. 
There is no single study in the UK that has looked at the visual pathway (part of 
the forebrain) in such detailed fashion, not only assessing structure and function 
of the vision in finer details, but also correlating it with important parameters of 
neurological function. The study over-all makes suggestion on visual 
parameters to be considered for early diagnosis, predicting prognosis and also to 
evaluate response to disease modifying treatment. 
The initial part of this section sums up the overall interaction of functional and 
structural visual parameters with the later part correlating it with key 
neurological tests.  
We suggest visual improvement and loss by the low-contrast acuity chart if 
there has been a 7-10 letter change in the overall visual scores. The importance 
of Sloan 1.25% chart and Sloan 2.5% chart in detecting visual changes cannot 
be emphasised enough. Sloan forms a sensitive test for asymptomatic visual loss 
in MS. 
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Assessment of colour vision using the HRR chart helps to specify the type of 
colour deficiency and also drives home the concept of asymptomatic loss of 
colour vision.  The HRR chart aims to target detection of deficit along the 
Magnocellular, Parvocellular pathway, paying special attention to blue yellow, 
Koniocellular pathway. 
The Mean deviation on Humphrey’s visual field shows correlation with the 
Sloan and HRR colour testing. The Blue yellow pathway which is most likely to 
be affected in MS can be tested with Sloan 1.25% chart along with HRR colour 
chart and the SWAP (short wavelength automated perimeter)  testing on visual 
field which specifically tests the target blue yellow pathway. 
The RNFL loss as has shown by OCT parameters correlate very well with 
outcomes on Sloan chart, HRR colour chart and visual field indices. The study 
also generates the importance of posterior pole testing protocol of OCT in 
symptomatic and asymptomatic optic neuropathy of multiple sclerosis. 
EDI-OCT has never been explored in MS and this study addresses the most 
important vascular tissue of the eye, the choroid. We have interesting 
preliminary findings on the choroid thickness in controls and disease and 
hoping this will open the door to a similar study with bigger numbers to 
establish the connection proposed in this study. Is choroid the hub for starts of 
immunological process and break down of blood retinal barrier! 
The RNFL axonal loss in patients with MS and controls are shown in Table 
14.1, depicting the magnitude of differences in means for OCT values. 
239 
 
Table 14.1: Depicting the magnitude of differences in means for vision and 
OCT values. 
        
MD=Mean deviation, PSD=pattern std deviation, M.vol=macular    volume, 
RNFL= retinal nerve fibre layer, GCIP= ganglion cell inner plexiform complex, 
EDI= Enhanced depth imaging and PPRNFL= peripapillary RNFL. 
 
 
Parameter Control 
Mean 
Disease 
Mean 
ON 
positive 
DMT 
group 
LogMAR 57 42 42 43 
Sloan 2.5% 49 22 12 21 
Sloan 1.25% 43 13 5 8 
MD -2.13 -4.74 -6.75 -5.2 
PSD -1.13 -5.4 -7.89 -5.2 
M.Vol 9.2 7.9 6.43 8.1 
RNFL 29.6 23.99 21.65 25.3 
GCIP 88.9 82.43 79.35 85.2 
EDI 261 262 185 254 
PPRNFL 92.76 85.91 79.75 82.2 
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The logistic regression on this composite data and the subsequent odds ratio 
calculation after application of Bonferroni’s correction is depicted in figure 
14.2.  
Figure 14.2 
Logistic regression analyses demonstrating capacity for Sloan visual function test to predict 
multiple sclerosis (MS) vs disease-free control status in a heterogeneous MS cohort, 
accounting simultaneously for age. Odds ratios in favor of participants with worse vision 
scores being MS patients (versus disease-free controls) were greatest for low-contrast letter 
acuity (Sloan charts). It distinguishes MS patients from disease-free control subjects, even 
after accounting for age differences between the two groups. 
 
This study provides the data demonstrating that low-contrast acuity scores 
capture unique aspects of dysfunction not captured by standard neurologic 
scales of EDSS or the MSFC, suggesting that adding a visual component to the 
MSFC would increase the applicability of this measure. 
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Vision-Specific Quality of Life (QOL) Measures 
The role of patient related measures on quality of life and vision has not been 
explored completely. Irrespective of the disease, it is very important to get the 
patient perspective in disease and how it affects their quality of life and vision. 
As this study is already looking into multifactorial aspects, we designed our 
own quality of life and vision assessment questionnaire as shown below. This 
was further related to structure and function parameters of vision and MS. 
Collectively, these data demonstrated that low-contrast acuity testing provides 
information on patient-reported aspects of vision. This is a key feature for 
clinical measures and a prerequisite for their use as primary outcomes in clinical 
trials. 
Table 14.5: Quality of Life / Vision and its correlation to EDSS and Sloan’s chart 
Cases N=55 Unaffected Affected , but 
managing 
Affected, not 
managing 
Quality of vision 15 32 8 
Quality of life  2 37 16 
Binocular Sloan  chart 
1.25% 
12  (VA<6/12) 36 (VA 6/12-6/36) 4 (>6/36) 
EDSS  4(EDSS <3) 46(EDSS 3-6) 5(EDSS >6) 
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Quality of life and binocular vision outcome are highly corelated , making 
assessment in visual outcome more depictive of the patient outcome 
measures.Quality of vision on the other hand is a highly sensitive measure 
which affects many patients even before it is evident on the Sloan binocular 
chart. EDDS is a crude measure of  patient outcome and shows a wide variation 
to quality of life and outcome measures.Importantly, greater degrees of 
binocular summation were predictive of better patient outcome by the QOL 
(P=0.02) and QOV (P=0.03), indicating that the capacity to use both eyes 
together is an important factor in determining how well patients with MS can 
perform daily activities. 
This suggests assessing patients quality of life and vision  on an yearly basis 
using the standard  MS-QOL 54 and NEI-VFQ-25 is crucial and informative. 
Patient outcome measures have not been used to its best potential until date. 
Larger studies and additional meta-analyses will allow us to further refine the 
precision of these representative average values. 
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OCT Investigations in MS and ON 
In our study, which utilized spectral domain OCT to assess the RNFL.  45 eyes 
with MS who had a previous event of acute optic neuritis (ON) were analysed. 
The thickness of the RNFL was shown to be reduced by 46% in the affected 
eyes of the patients with MS versus the control eyes (P<0.01), and by check 
11% when affected eyes were compared with the ‘unaffected’ eyes of the same 
patient (P<0.01). Even in the clinically unaffected eyes of patients, however, 
there was a 26% reduction in RNFL thickness when compared with control eyes 
(P<0.01). check whole para 
This finding is striking given that the RNFL is only about 110–120 µm thick by 
the age of 15 years, and that most healthy individuals (without a history of 
glaucoma or macular degeneration) will lose only about 0.017% per year in 
retinal thickness, which equates to approximately 10–20 µm over 60 years 
Testing patients with Low-contrast letter acuity in MS eyes with a history of 
acute ON, we found a threshold for abnormal visual function and axonal loss at 
85µm (Fig. 14.7). 
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Figure 14.7: Threshold for abnormal visual function and axonal loss 
Scatter 
plots showing relation of low-contrast letter acuity to retinal nerve fiber layer (RNFL) 
thickness in microns for eyes from a heterogeneous MS cohort with a history of acute optic 
neuritis (ON). The left panel shows eyes with abnormal low-contrast  at 2.5% contrast. 
Among eyes with abnormal low-contrast acuity, worse scores were significantly associated 
with lower (thinner) peripapillary RNFL, accounting for age and adjusting for within-patient, 
inter-eye correlations. 
The time course of RNFL axonal loss following an episode of acute ON is an 
important for determining the “window of opportunity” within which a 
neuroprotective agent should be administered in a treatment trial.)  
One of the most important findings that has resulted from the use of OCT MS 
studies is the correlation between RNFL thinning and visual loss, as measured 
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by low-contrast letter acuity. We found that RNFL thickness was reduced 
significantly among MS patients (92 µm) versus controls (105 µm, P<0.001), 
and particularly reduced in MS ON eyes (85 µm, P<0.001) 
 Assessment done on the Optic nerve head OCT revealed interesting results. 
Sectoral RNFL atrophy was a striking feature in our cohort of patients. There 
was an evidence of significant drop in the inferior and superior nasal fibres and 
widening of vertical cup disc ratio. The optic nerve looked overall pale with 
inferior and superior rim thinning resembling the disc of glaucomatous optic 
neuropathy.  This possible reflects that the final pathway for the death of 
neurons in MS may be similar to that  in glaucoma .For those interested in optic 
neuropathies, the comparison of  optic neuropathy in Glaucoma to that of 
Multiple sclerosis may further be explored using the Glaucoma premium model 
OCT protocol on Spectralis OCT. 
Table14.8:  Comparison of sectoral RNFL in disease and control: 
Mean values 
microns  
Superior RNFL Inferior RNFL Nasal RNFL Temporal 
RNFL 
Control 
N=50 
98.8 102 63 54 
Disease  
N=110 
83 78 59 49 
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Figure 14.9: Predominant loss in the superior and inferior rim, inferior 
more marked in this cohort. 
14.10: Bar chart depicting the intensity of loss of superior and inferior 
nerve fiber in disease 
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                                Chapter 15:  The Final conclusion 
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Final conclusion: 
 
Multiple sclerosis is a progressive disease leading to significant disability 
affecting quality of life and has a huge social and financial burden on the 
department of health. 
 
Vision studies in our project has shown to be very specific and sensitive 
 in detecting disease  and to determine the prognosis in RRMS .Visual 
assessments have a synergistic value to other tests such as MSFC, EDSS and 
MRI. 
 
Visual charts  
Snellen’s chart has been a very routinely used chart in most NHS trust across 
England and Wales. The UHNM has now moved on to using the ETDRS charts 
since 2013.The ETDRS chart is a  LogMAR chart that has been used in the 
research project to compare it with the Sloan 2.5% and 1.25% contrast charts. 
Sloan chart are not a routine visual testing method and is in use only at the level 
of clinical trials in Multiple sclerosis. 
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Snellen’s chart has shown to have a poor specificity and sensitivity in detecting 
the control and the disease. The limitations of the test chart take an upper hand 
and make it a less reliable method of vision testing. 
 
LogMAR chart is comparable to the Sloan 2.5% chart, though the 1.25% chart 
has showed to more sensitive with a high odds ratio .The ROC curve also shows 
the rate of identification of disease versus control to be better on Sloan 1.25% 
chart. Sloan 1.25% has the ability to identify visual defects at an early stage and 
hence this chart may see a good use in the visual pathway assessment in future.  
 
We are still using the Ishihara charts to detect colour deficit in all eye 
conditions. Ishihara along with Snellen’s make a very poor combination of 
visual tests giving very little information of the condition. Why we still continue 
to use it, is not very clear. As we all know, changing old practise is hard and 
takes time. Hope this is the era for the change in approach to visual assessment 
in MS. 
 
The HRR chart showed color deficits of varying nature in the positive and 
negative optic neuritis cohort, with an ability to detect the type and extent of 
colour deficit. The HRR Chart has a potential of detecting early changes in the 
very sensitive koniocellular pathway even before it is evident on visual testing 
by Sloan 2.5% chart. The HRR chart and Sloan 1.25% chart form a good pair of 
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test to determine the prognosis of disease and in detection of changes in 
asymptomatic patients. Studies with bigger numbers are required to explore the 
potential of the 2 tests in combination. 
Age at optic neuritis seem to have an effect on the outcome with early onset 
optic neuritis showing better prognosis than the late onset type. 
We would like to explore this further in our future studies. 
 
OCT is the future in assessment of visual pathway in MS. It is sensitive with 
high inter and intra test reliability.  
The RNFL layer and macular volume seem to be sensitive in detecting changes 
in the un myelinated RNFL. Much has been spoken about the GCIP and 
manual/ automated segmentation, though, our research showed not much gain 
from it. Additionally, it is time consuming and can make OCT bit complicated 
to those who are trying to incorporate OCT in their day to day protocol. 
 
The posterior pole OCT has not been spoken of in previous research work 
globally. Our research project found a great potential for the Posterior pole 
protocol OCT and the element of structure comes to life when compared with 
function as tested by the visual field sensitivity on Humphrey’s field test. Work 
needs to be done, though we had significant p value correlating both the 
parameters. The down side of this combination is the time consumption of 
visual field and the fatigue that can be exaggerated for patients with MS. In our 
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cohort, we had reliable field at the first attempt though, we think, it may be 
variable if the cohort of patients included SPMS and PPMS. 
 
EDI OCT has been used in our study as MS is an autoimmune demyelination. A 
contribution from the choroid was thought as it is embryologically similar to the 
choroidal plexuses in the brain. 
Our study is the first of the kind which shows the thickness of the choroid to be 
variable. We are not able to strongly prove that EDI OCT is very diagnostic due 
to the low recruitment score and also that we did not give much importance at 
the time of conducting the research examination. 
 
More studies from our group will be done in future on EDI OCT depending on 
staffing, ethics and interest of future researchers. 
 
We have specific interest in studying the so called OSMS group. We plan to 
study the Aquaporin genes along with MRI and EDI OCT in the future vision 
studies. 
 
This study was designed in 2009 even before any study from the American 
group was published on structure and function. Funding and ethics are a major 
hindrance to the take-off of a research project in the UK. Our study also 
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underlines the importance of patient related measure of quality of life and vision 
which adds more value than any testing parameters.  
It is very important to know what this parameter on vision translates in the day 
to day life of a patient, without which most tests are incomplete. 
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15.4. Revisiting the key points.  
 
1. Structural loss of neurons in the anterior visual pathway as determined 
by OCT correlates with the functional loss of vision as determined by 
Sloan’s contrast chart. 
2. HRR (Hardy Rand Rittler) colour chart is a very sensitive test for colour 
vision in Multiple sclerosis and Optic neuritis. It not only detects 
symptomatic and asymptomatic optic neuritis, but also, grades the extent 
of damage.  
3. Age of onset of optic neuritis in MS determines the rate at which 
ganglion cell layer is lost. The results of patients with early onset optic 
neuritis have better outcome measure compared to the late onset type of 
optic neuritis. This may relate to the variation in macrophagic activity in 
the optic nerve in the younger age group.  
4. The thickness of choroid in MS patients, as measured by the EDI OCT, 
is significantly variable than the control groups. A further study with a 
bigger sample size is indicated by this project.  
5.  Posterior pole thickness on OCT closely correlates to the sensitivity 
(point-point) of the visual fields as tested by SITA standard Humphrey’s 
visual fields testing. This positive correlation can be exploited in early 
diagnosis and response to treatment in MS.  
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6. RNFL thickness as determined by the serial OCT’s of the optic nerve 
head is a valuable tool to diagnose asymptomatic optic neuropathy.  
7.  Alterations in the ganglion cell layer thickness and inner nuclear layer 
thickness is directly related to functional measures in MS.  
8. Retinal segmentation OCT findings do not give any extra information 
when compared to other functional scores on visual testing. 
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1) Optico-spinal MS in British Caucasians (First Author): A study of clinical 
features, radiological features and genetics relating to NMO antibodies.  
Multiple Sclerosis Journal, October 2011; vol. 17, 10 suppl: pp. S507-
S524.  
2) Progression of disability in multiple sclerosis: A study of factors 
influencing median time to reach an EDSS value. Multiple Sclerosis and 
Related Disorders, Volume 2, Issue 2, Pages 109-116 , Oct 2012.  
3)  Increased frequency of IL17-IL22 dual secreting Tcells in 
relapsing/remitting multiple sclerosis. (2014)  
doi: 10.1177/1352458514547848  
Mult Scler September 2014 vol. 20 no. 1 suppl 501-510  
  
International Posters and Presentations 
 
 
4) International presentation (first author) and poster at the European and 
American society for research in MS (2011) in the highly privileged late 
breaking news section of the meeting at Gothenburg, Sweden. “Optico-
spinal MS in British Caucasians: A study of clinical features, radiological 
features and genetics relating to NMO antibodies”.  
5) “NMO antibodies in Optico spinal MS”: Presentation (first author) at 
2012 European Charcot’s meeting for Young investigators award. 
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6) ACTRIMS-ECTRIMS Boston 2014: Late Breaking News  
Increased frequency of IL17-IL22 dual secreting Tcells in 
relapsing/remitting multiple  
 
Grant applications as primary author 
7) Primary author for a grant application through SHINE (UK). We aimed to 
unravel an exciting phenomenon of CCSVI- chronic cerebrospinal venous 
insufficiency in MS. 
8) Submitted a fellowship grant application through the ECTRIMS 
committee 2012.  
Nominations 
9) I have been nominated for the European young investigators award and 
the West Midlands Vitae prize.  
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Sub Investigator to Keele MS Clinical Trial Unit: 
 
I have been a sub-investigator to 13 clinical trials as an Ophthalmologist with 
Neurostatus qualification for clinical trials. 
1) Phase II study of oral Fingolimod (FTY720) in multiple sclerosis and a 
24-month extension of a phase II trial assessing the efficacy, safety, and 
tolerability of the once-daily oral sphingosine-1-phosphate receptor 
modulator, Fingolimod, in relapsing multiple sclerosis (MS). I also 
contributed to monitoring the macular oedema on OCT. 
2) A PIC site for a Phase II Double Blind, Randomized, Placebo Controlled 
Trial of  Neuroprotection With Phenytoin in Acute Optic Neuritis. 
3) A randomized, double-blind, double-dummy, parallel-group study to 
evaluate the efficacy and safety of Ocrelizumab in comparison with Rebif 
(interferon beta-1a) in patients with relapsing multiple sclerosis. 
(OPERA) 
4) A Phase III, randomized, double-blind, placebo-controlled, multi-centre 
clinical trial of oral Cladribine in subjects with a first clinical event at 
high risk of converting to MS (ORACLE MS). 
5)  A Double-Blind, Multicenter, Extension Study to Evaluate the Safety 
and Efficacy of DAC HYP in Subjects with Multiple Sclerosis Who Have 
Completed Treatment in Study 205MS201 (SELECT-re study) 
6) An open label multicenter, extension study to evaluate the safety and 
tolerability of Natalizumab following re-initiation of dosing in multiple 
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sclerosis subjects who have completed study C-1801 or C1802 and a 
dosing suspension safety evaluation.(Tysabrii) 
7) Long-term extension of the multinational, double-blind, placebo 
controlled study EFC6-40 (HMR 1726D/3001) to document the safety of 
two doses of Teriflunomide (7 and 14mg) in patients with multiple 
sclerosis with relapses (TEMSO ext. study) 
8) Long-term extension of the multinational, double-blind, placebo 
controlled studies PDY6045 and PDY6046 to document the safety of 
Teriflunomide when added to treatment with interferon or Glatiramer 
acetate in patients with multiple sclerosis with relapses 
9) A randomised double blind placebo-controlled parallel group multi-centre 
trial of Cannabinoids to slow progression in multiple sclerosis. (CUPID 
study). 
10) Multinational, Multicentre, Randomised, Double-Blind, Placebo   
Controlled, Parallel Group Study to evaluate the effect of early 
Glatiramer acetate treatment in delaying the conversion to clinically 
definite multiple sclerosis of subjects presenting with a clinically isolated 
syndrome (PRECISE study) 
11) A Phase III, Double-Blind, Placebo-Controlled, Multicentre, 
Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of 
Oral Cladribine in Subjects with Relapsing-Remitting Multiple Sclerosis 
Who Have Completed Trial 25643 (CLARITY) 
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X9 BE   N   43   13 8 NORMAL 
X9 RE       35   13 8   
X9 LE       42   12 8   
X10 BE   N   50   35 10 NORMAL 
X10 RE       45   32 10   
X10 LE       43   35 8   
X11 BE       45   25 10   
X11 RE   Y 1990 15   3 1 MILD RG 
X11 LE       43   22 10   
X12 BE   N   22   1 0 MILD RGR 
X12 RE       12   1 0   
X12 LE       21   1 0   
X13 BE   Y 1994 35   6 1 MOD RG 
X13 RE       35   3 0   
X13 LE       35   6 1   
X14 BE   N   56   34 24 NORMAL 
X14 RE       55   35 21   
X14 LE       55   35 21   
X15 BE   N   37   15 12 NORMAL 
X15 RE       36   13 13   
X15 LE       36   15 12   
X16 BE   Y 1996 5   0 0 N/A 
X16 RE       3   0 0   
X16 LE       4   0 0   
X17 BE   N   60   45 35 NORMAL 
X17 RE       58   43 35   
X17 LE       59   43 36   
X18 BE   N   45   22 16 N 
X18 RE       32   21 16   
X18 LE       43   22 14   
X19 BE   Y 2012 3   0 0 NORMAL 
X19 RE       4   0 0   
X19 LE       2   0 0   
X20 BE   N   60   45 35 NORMAL 
X20 RE       58   46 36   
X20 LE       54   43 35   
X21 BE   Y 2013 54   10 3 MILD RG 
X21 RE       55   8 1   
X21 LE       53   4 1   
X22 BE       54   25 4   
X22 RE   Y 2009 23   5 0 MILD RG 
X22 LE       52   20 3   
X23 BE   N   45   26 18 NONE 
X23 RE       32   20 17   
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X23 LE       32   22 18   
X24 BE   N   22   3 0 NONE 
X24 RE       12   0 0   
X24 LE       22   3 0   
X25 BE       54   45 35   
X25 RE       53   43 35   
X25 LE   Y 1990 54   45 35   
X26 BE   N   21   3 2 NORMAL 
X26 RE       12   3 1   
X26 LE       22   1 1   
X27 BE   Y 2003 21   4 1 NORMAL 
X27 RE       17   2 1   
X27 LE       14   2 0   
X28 BE   N   54   11 5 NORMAL 
X28 RE       53   11 5   
X28 LE       51   11 5   
X29 BE       43   3 1 MOD RG 
X29 RE   Y 2006 12   0 0   
X29 LE       42   2 1   
MEAN 
   
42.55 mean 22.56954 14.07947 
 MEDIAN 
   
45 
 
25 10 
 SDP 
   
14.67516 
 
14.53541 12.87974 
 IQR- 
   
19.5 
 
25 23.5 
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Name m-vol edi Mrnfl gcip pprnfl     ON   1.25%chart COLOR  
LS BE               Y SEVERE 22   
LS RE 8.84 215 22.6 78.8 92         22 NORMAL 
LS LE 8.76 235 21.4 76.2 91         0 NORMAL 
KS BE                    24   
KS RE 7.23 280 18.3 72.2 60     YES   24 NORMAL 
KS LE 7.46 295 23.2 84.2 82     NO   46 NORMAL 
JB BE               YES   20   
JB RE 8.64 265 25.4 85.4 91     Y   0 MILD RG 
JB LE 8.77 220 26.8 86.3 96     Y   14 NORMAL 
CB BE                   45 NORMAL 
CB RE 8.59 270 26.6 89.9 110     AMBLYOPIA 25    NORMAL 
CB LE 8.44 290 21 74.2 93     YES 1988 45 NORMAL 
SCR 
BE                   9   
SCR 
RE 6.88 342 11.1 64 60     
YES, 
SEVERE 2004 0 MEDIUM RG 
SCR LE 7.65 265 27.9 89 77         9   
CS BE 
       
N 
 
0 NORMAL 
CS RE 8.3 272 28.4 91.2 86     N 
 
0 NORMAL 
CS LE 8.54 243 26.8 87 87     N 
 
0 NORMAL 
MA BE               N   25 NORMAL 
MA RE 9.47 159 32.3 94 85     N   0 NORMAL 
MA LE 6.88 356 22.2 81 73     N   25 NORMAL 
SB BE                   25 NORMAL 
SB RE 7.5 260 24.6 88 82         25 NORMAL 
SB LE 7.1 292 21.7 84 78         15 
MILD RG 
DEUTAN 
KM BE                   40 NORMAL 
KM RE 7.71 221 26.2 94 98         30 NORMAL 
KM LE 7.65 265 25.8 94 94         25 NORMAL 
PD BE                   0 
RG/BY 
STRONG 
PD RE 10.17 117 29.2 104 63         0 
RG/BY 
STRONG 
PD LE 8.51 283 20.01 79 64     Y 1994 0 
RG/BY 
STRONG 
JA BE               N   15 NORMAL 
JA RE 7.87 280 19.34 74 75         15 NORMAL 
JA LE 7.87 320 18.64 73 69         11 MILD DEUTAN 
JT BE               Y 2004 6   
JT RE 7.73 310 16.7 69 63         1 MILD RG 
JT LE 7.78 298 18.56 78 68         2 MILD RG 
AC BE               N   35 NORMAL 
AC RE 8.68 220 28.7 89 104         30 NORMAL 
ACLE 8.76 234 30.23 91 102         25 NORMAL 
PE BE               N   30 NORMAL 
PE RE 8.7 242 30.98 92 70         24 NORMAL 
PE LE 8.77 247 31.07 93 94         23 NORMAL 
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SS BE               N   25 NORMAL 
SS RE 8.88 210 29.5 96 103         9 NORMAL 
SS LE 9.03 140 32.54 97 102         4 NORMAL 
KT BE               N   15 NORMAL 
KT RE 8.34 284 25.6 86 103         5 NORMAL 
KT LE 8.54 275 26.4 89 96         1 NORMAL 
DG BE               Y 2000 35   
DG RE 7.95 339 19.3 76 60         4 MILD RG 
DG LE 8.78 250 26.3 95 78         10 NORMAL 
VD BE                   30   
VD RE 8.5 236 20.6 77 110     Y 2012 20 MILD RG 
VD LE 8.56 223 23.7 85 111     Y   10 MILD RG 
JC BE               N   20 NORMAL 
JC RE 9.1 263 29.6 96 96         2 NORMAL 
JC LE 9.26 263 31.9 98 100         2 NORMAL 
NW BE               N   35 NORMAL 
NW RE 8.7 220 32.9 97 120         20 NORMAL 
NW LE 8.2 280 28.9 93 96         31 NORMAL 
BS BE                   40 NORMAL 
BS RE 9.8 160 28.6 87 103         40 NORMAL 
BS LE 9.7 175 29.7 89 101         40 NORMAL 
DN BE                   30 NORMAL 
DN RE 8.43 252 28.7 79 85         9 NORMAL 
DN LE 8.59 213 29.7 81 83     AMBLYOPIA 0 NORMAL 
X1 BE               Y 1994 30 NORMAL 
X1 RE 7.65 297 18.6 72 65         20 NORMAL 
X1 LE 7.86 265 22.3 83 76         25 NORMAL 
XE BE                   10   
X2 RE 6.8 318 16.1 71 58     Y 2010 0 MILD RG 
X2 LE 7.65 265 21.7 81 78         10 NORMAL 
X3 BE               N   10 NORMAL 
X3 RE 8.45 236 26.7 87 98         10 NORMAL 
X3 LE 8.3 265 25.3 82 86         10 NORMAL 
X4 BE               Y 2012 8 MILD RG BE 
X4 RE 6.54 367 12.7 69 56         6   
X4 LE 6.9 321 13.9 68 62         5   
X5 BE               N   15 NORMAL 
X5 RE 7.98 320 22.4 83 96         15   
X5 LE 8.3 276 27.6 89 103         10   
X6 BE               Y 1990 25 MILD RG 
X6 RE 7.9 312 20.4 73 89         15   
X6 LE 8.1 267 24.2 79 92         12   
X7 BE               N   25 NORMAL 
X7 RE 7.34 301 25.5 87 87         24   
X7 LE 7.65 285 27.5 89 93         25   
X8 BE                   9   
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X8 RE 7.98 264 27.67 89 103         10   
X8 LE 6.5 324 12.6 65 72     Y 2007 0 MOD RG 
X9 BE               N   8 NORMAL 
X9 RE 7.24 302 27.8 87 78         8   
X9 LE 8.1 267 25.3 82 93         8   
X10 BE               N   10 NORMAL 
X10 RE 8.4 224 28.7 92 110         10   
X10 LE 8.6 213 29.7 93 113         8   
X11 BE                   10   
X11 RE 7.8 312 21.9 84 97     Y 1990 1 MILD RG 
X11 LE 8.5 265 28.3 91 109         10   
X12 BE               N   0 MILD RGR 
X12 RE 7.6 286 26.7 87 96         0   
X12 LE 7.9 265 28.1 91 97         0   
X13 BE               Y 1994 1 MOD RG 
X13 RE 7.1 280 14 62 62         0   
X13 LE 7.2 234 13.8 56 56         1   
X14 BE               N   24 NORMAL 
X14 RE 9.1 167 26.1 86 86         21   
X14 LE 8.9 187 25.9 84 83         21   
X15 BE               N   12 NORMAL 
X15 RE 7.8 264 23.4 82 92         13   
X15 LE 7.6 256 24.2 84 95         12   
X16 BE               Y 1996 0 N/A 
X16 RE 7.1 310 21.4 74 77         0   
X16 LE 7.5 302 23.3 76 76         0   
X17 BE               N   35 NORMAL 
X17 RE 8.1 243 27.9 87 98         35   
X17 LE 8.5 213 28.76 87 103         36   
X18 BE               N   16 N 
X18 RE 7.35 286 23.4 79 78         16   
X18 LE 7.54 310 24.7 81 82         14   
X19 BE               Y 2012 0 NORMAL 
X19 RE 5.67 178 12.4 72 58         0   
X19 LE 6.5 156 13.6 75 67         0   
X20 BE               N   35 NORMAL 
X20 RE 8.2 267 26.5 87 103         36   
X20 LE 8.25 243 25.07 89 98         35   
X21 BE               Y 2013 3 MILD RG 
X21 RE 6.3 143 12.8 69 69         1   
X21 LE 6.4 156 13.2 71 72         1   
X22 BE                   4   
X22 RE 7.5 280 22 76 86     Y 2009 0 MILD RG 
X22 LE 8.1 232 25.3 87 92         3   
X23 BE               N   18 NONE 
X23 RE 8.21 213 26.7 86 98         17   
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X23 LE 7.69 296 25.5 79 95         18   
X24 BE               N   0 NONE 
X24 RE 8.97 145 31.2 88 103         0   
X24 LE 9.3 169 33.2 95 114         0   
X25 BE                   35   
X25 RE 7.9 267 26.1 86 82         35   
X25 LE 7.23 287 21.6 76 76     Y 1990 35   
X26 BE               N   2 NORMAL 
X26 RE 6.56 342 17.3 72 64         1   
X26 LE 7.21 289 22.3 79 72         1   
X27 BE               Y 2003 1 NORMAL 
X27 RE 10.43 185 26.3 96 115         1   
X27 LE 10.01 135 25.7 93 103         0   
X28 BE               N   5 NORMAL 
X28 RE 10.02 134 29.5 94 92         5   
X28 LE 9.96 154 31.2 93 86         5   
X29 BE                   1 MOD RG 
X29 RE 5.76 156 12 65 53     Y 2006 0   
X29 LE 8.3 289 27.3 86 84         1   
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LogMAR 
 
2.50% 1.25% 
50   33 22 
45   33 22 
30   11 0 
60   13 24 
50   18 24 
55   45 46 
55   34 20 
55   25 0 
55   30 14 
51   45 45 
30   20 25 
50   30 45 
57   60 9 
30   0 0 
57   22 9 
55 
 
6 0 
50 
 
6 0 
55 
 
14 0 
41   34 25 
41   30 0 
34   28 25 
60   30 25 
60   30 25 
45   20 15 
60   40 40 
60   40 30 
55   30 25 
40   3 0 
30   0 0 
25   0 0 
51   25 15 
49   25 15 
32   10 11 
45   16 6 
45   14 1 
42   1 2 
60   43 35 
55   29 30 
50   25 25 
60   45 30 
60   39 24 
55   38 23 
60   35 25 
55   30 9 
55   30 4 
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50   24 15 
45   20 5 
40   10 1 
51   35 35 
44   25 4 
48   30 10 
50   40 30 
50   24 20 
50   25 10 
55   40 20 
55   30 2 
50   25 2 
55   41 35 
50   39 20 
50   41 31 
50   40 40 
50   40 40 
50   40 40 
50   30 30 
40   14 9 
20   0 0 
55   35 30 
50   30 20 
54   34 25 
50   25 10 
45   15 0 
50   25 10 
45   25 10 
32   20 10 
45   20 10 
35   20 8 
25   15 6 
32   18 5 
35   40 15 
25   35 15 
32   40 10 
50   35 25 
54   30 15 
45   29 12 
43   35 25 
42   35 24 
43   32 25 
60   25 9 
58   24 10 
23   3 0 
43   13 8 
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35   13 8 
42   12 8 
50   35 10 
45   32 10 
43   35 8 
45   25 10 
15   3 1 
43   22 10 
22   1 0 
12   1 0 
21   1 0 
35   6 1 
35   3 0 
35   6 1 
56   34 24 
55   35 21 
55   35 21 
37   15 12 
36   13 13 
36   15 12 
5   0 0 
3   0 0 
4   0 0 
60   45 35 
58   43 35 
59   43 36 
45   22 16 
32   21 16 
43   22 14 
3   0 0 
4   0 0 
2   0 0 
60   45 35 
58   46 36 
54   43 35 
54   10 3 
55   8 1 
53   4 1 
54   25 4 
23   5 0 
52   20 3 
45   26 18 
32   20 17 
32   22 18 
22   3 0 
12   0 0 
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22   3 0 
54   45 35 
53   43 35 
54   45 35 
21   3 2 
12   3 1 
22   1 1 
21   4 1 
17   2 1 
14   2 0 
54   11 5 
53   11 5 
51   11 5 
43   3 1 
12   0 0 
42   2 1 
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This spreadsheet performs Spearman rank correlation on up to 1000 observations.  
  For more information, see http://udel.edu/~mcdonald/statspearman.html.   
  It comes with the frigatebird data from that page entered as an example.   
  To use the spreadsheet, replace the frigatebird data with your numbers.   
                    
  If you have fewer than 11 observations, the P values from the equation are inaccurate. 
  In that case, the P-values are looked up in a table of critical values, and you should use this "P-value from table" instead. 
  
 
COLOUR 
         
  
LogMAR rank of x rank of y 
      
 
35 
 
15.5   
 
Spearman's rho: 0.711 
 
O.43083 
 
 
35 35 50 50.5 
 
degrees of freedom: 97 
   
  
35   50.5 
 
P-value: 1.67|E-16 
   
 
36 
 
15.5   
 
    
  
0.923477 
 
36 36 15.5 15.5 
      
  
36   15.5 
      
 
32 
 
73   
      
 
35 32   74 
      
  
35   50.5 
      
 
35 
 
50   
      
 
36 35 15.5 50.5 
      
  
36   15.5 
      
 
28 
 
85   
      
 
36 28 15.5 86 
      
  
36   15.5 
      
 
36 
 
15.5   
      
 
36 36 15.5 15.5 
      
  
36   15.5 
      
 
35 
 
50   
      
 
36 35 15.5 50.5 
      
  
36   15.5 
      
 
35 
 
50   
      
 
30 35 79.5 50.5 
      
  
30   80.5 
      
 
35 
 
50   
      
 
36 35   50.5 
      
  
36   15.5 
      
 
4 
 
97   
      
 
2 4 98 98 
      
  
2   99 
      
   
    
      
 
33 
 
70   
      
  
33   71 
      
 
32 
 
73   
      
 
30 32 79.5 74 
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30   80.5 
      
 
35 
 
50   
      
 
35 35 50 50.5 
      
  
35   50.5 
      
 
35 
 
50   
      
 
36 35 15.5 50.5 
      
  
36   15.5 
      
 
35 
 
50   
      
 
35 35 50 50.5 
      
  
35   50.5 
      
 
36 
 
15.5   
      
 
36 36 15.5 15.5 
      
  
36   15.5 
      
 
30 
 
79.5   
      
 
35 30 50 80.5 
      
  
35   50.5 
      
 
29 
 
83   
      
 
31 29 76.5 84 
      
  
31   77.5 
      
 
35 
 
50   
      
 
35 35 50 50.5 
      
  
35   50.5 
      
 
35 
 
50   
      
 
35 35 50 50.5 
      
  
35   50.5 
      
 
35 
 
50   
      
 
36 35 15.5 50.5 
      
  
36   15.5 
      
 
36 
 
15.5   
      
 
36 36 15.5 15.5 
      
  
36   15.5 
      
 
35 
 
50   
      
 
36 35 15.5 50.5 
      
  
36   15.5 
      
 
29 
 
83   
      
 
35 29 50 84 
      
  
35   50.5 
      
 
35 
 
50   
      
 
36 35 15.5 50.5 
      
  
36   15.5 
      
 
25 
 
86.5   
      
 
22 25 93 87.5 
      
  
22   94 
      
 
35 
 
50   
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36 35 15.5 50.5 
      
  
36   15.5 
      
 
23 
 
90.5   
      
 
23 23 90.5 91.5 
      
  
23   91.5 
      
 
35 
 
50   
      
 
35 35 50 50.5 
      
  
35   50.5 
      
 
35 
 
50   
      
 
21 35 95 50.5 
      
  
21   96 
      
 
36 
 
15.5   
      
 
36 36 15.5 15.5 
      
  
36   15.5 
      
 
35 
 
50   
      
 
36 35 15.5 50.5 
      
  
36   15.5 
      
 
32 
 
73   
      
 
35 32 50 74 
      
  
35   50.5 
      
 
32 
 
73   
      
 
30 32 79.5 74 
      
  
30   80.5 
      
 
25 
 
86.5   
      
 
24 25 88.5 87.5 
      
  
24   89.5 
      
 
35 
 
50   
      
 
35 35 50 50.5 
      
  
35   50.5 
      
 
35 
 
50   
      
 
35 35 50 50.5 
      
  
35   50.5 
      
 
0 
 
100   
      
 
1 0 99 101 
      
  
1   100 
      
 
35 
 
50   
      
 
35 35 50 50.5 
      
  
35   50.5 
      
 
36 
 
15.5   
      
 
35 36 50 15.5 
      
  
35   50.5 
      
 
36 
 
15.5   
      
 
36 36 15.5 15.5 
      
  
36   15.5 
      
289 
 
 
36 
 
15.5   
      
 
36 36 15.5 15.5 
      
  
36   15.5 
      
 
32 
 
73   
      
 
29 32 83 74 
      
  
29   84 
      
 
31 
 
76.5   
      
 
35 31 50 77.5 
      
  
35   50.5 
      
 
35 
 
50   
      
 
36 35 15.5 50.5 
      
  
36   15.5 
      
 
22 
 
93   
      
 
19 22 96 94 
      
  
19   97 
      
 
35 
 
50   
      
 
36 35 15.5 50.5 
      
  
36   15.5 
      
 
36 
 
15.5   
      
 
36 36 15.5 15.5 
      
  
36   15.5 
      
 
35 
 
50   
      
 
35 35 50 50.5 
      
  
35   50.5 
      
 
35 
 
50   
      
 
36 35 15.5 50.5 
      
  
36   15.5 
      
 
24 
 
88.5   
      
 
22 24 93 89.5 
      
 
 
